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Chromosomes are replicated by the replisome, a molecular machine comprised of a 
set of interacting proteins with interdependent functions. In previous work, a fragment 
library was screened in vitro against a bacterial replisome, reconstituted from thirteen 
different subunits. In this thesis, the results of this phenotypic assay were validated, 
analysed and extended with functional and biophysical experiments to explore 
different mechanisms of inhibition. �e work shows that phenotypic fragment 
screening can be used as a starting point for target identification. 
Assays for the individual protein complexes in the replisome revealed that most 
fragment inhibitors acted through specific proteins. For one fragment inhibitor, the 
results were consistent with inhibition of primase, an enzyme that synthesises short 
primers to initiate elongation. �e mode of action of this fragment and analogues were 
studied in detail. 
�e bacterial primase consists of three domains: a helicase-binding, a zinc-binding, 
and a polymerase domain. �e fragment was not observed to bind to the polymerase 
domain in X-ray crystallography and nuclear magnetic resonance experiments. 
Molecular dynamics simulations showed a clear preference for binding to a conserved 
protein-protein interaction site on the helicase-binding domain, rather than to the zinc-
binding domain. �is prediction was validated by protein-observed nuclear magnetic 
resonance experiments and structure-activity and -affinity relationships.  
Some of the replisome fragment inhibitors acted only on the full machine and do not 
show inhibition of the available assays for individual components. Methods were 
developed to generate and test photoreactive fragment hit analogues and to screen 
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1.1 Fragment-based lead discovery 
Modern Western drugs most often contain single, rationally designed active 
ingredients. �e majority of these active ingredients can be classed into three groups: 
small organic molecules, large organic molecules, and infectious single particles such 
as virions and bacterial cells; the first being the largest group. Rational design of novel 
small organic molecules for therapeutic use depends heavily on scientific methods, so 
that newly developed methods have often contributed to development of new drugs.  
Drug development projects start with a predefined target product profile: e.g. a 
successful drug candidate will cure disease X while side effects remain below level Y. 
�e complete drug development process is often long (4-20 years) and has a low 
chance of success. It involves many different steps requiring many different scientific 
and other types of expertise. �e very first step in the process is to hypothesise a 
mechanism for interfering with the disease, based on available biological information. 
�e hypothesis is almost always based on the central idea that biological effects are 
caused by the physical interaction of two molecules, most often a protein and a small 
organic molecule. �is first step is not always required, as will be discussed later. �e 
second step in the process is to identify one or more drug candidates, or ‘leads’. �ese 
early stages are called lead discovery. Many other steps after this will focus on 
selecting and transforming leads into actual small molecule drugs, the active 
ingredients in most medicines.  
When the target and desired effect are known, the discovery process often starts with 
the screening of a diverse library of organic compounds. Screening random 
compounds may seem like a rather blunt method, but currently it remains the most 
effective approach to find hits. Other approaches are mostly based on mimicking or 
repurposing known drugs and natural molecules, which do not give much novelty in 
either medical or business sense. Screening of large collections of compounds (up to 
several millions) can be done efficiently by using robotics and automation. �is is 
called high-throughput screening (HTS) and has become a standard procedure in the 
pharmaceutical industry since the 1980s. However, HTS is not accessible to anyone 
outside the pharmaceutical industry due to the high costs of maintaining not only 
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screening infrastructure but also compound collections themselves. �ere are two 
main alternatives to HTS, both developed more recently and used by many academic 
groups and small as well as large enterprises. One is virtual screening, which does not 
require much physical equipment but does require sophisticated software for screening 
and analysis. �e other is fragment screening (Erlanson et al., 2016), the term 
‘fragment’ meaning a small part of an average-sized screening or drug molecule. 
Fragment-based screening and lead development (FBLD) does not require much 
physical equipment but does require more work to develop a fragment hit into an 
attractive lead compound. �e ideas and methods underlying FBLD have been under 
development since the 1970s and will be discussed below.  
1.1.1 Core concepts of fragment-based lead discovery 
A core concept of FBLD is that chemical space, the total number of possible small 
organic molecules, is smaller as the number of atoms in a compound decreases (Hall 
et al., 2014). �us, the usefulness of screening libraries containing 105-107 potential 
lead candidates, historically only available to big pharmaceutical companies, can be 
rivalled by libraries of just 102-104 fragment molecules (Shi & von Itzstein, 2019). �e 
differences between drug-like HTS compounds and fragments are illustrated by the 
crude ‘rules’ of five (Lipinski et al., 2001) and three (Congreve et al., 2003; Jhoti et 
al., 2013), referring to preferred values of selected physicochemical properties of 
organic screening compounds (e.g. molecular weight, hydrophobicity, number of 
hydrogen bond-forming atoms and rotatable bonds). Another useful way of 
comparison is to look at the number of non-hydrogen atoms (heavy atoms, HA): while 
HTS compounds average HA counts of >25, fragment hits often start off with <15 and 
fragment library members are limited to 20 at most (Keserű et al., 2016).  
Not only do fragments offer more efficient chemical space coverage, their hit rates are 
also higher compared to HTS libraries. �is is best thought of in terms of ‘molecular 
complexity’, a concept developed by Hann et al. (Hann et al., 2001; Leach & Hann, 
2011). Both a screening compound and a receptor pocket can be viewed as a collection 
of chemical features (e.g. hydrogen bond donors/acceptors) in a certain spatial 
configuration, that either attract or repel each other. Hits are molecules that 
complement the receptor features and thus favour binding. Bigger molecules have 
more complex feature patterns, which decreases the probability of finding the right 
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complementary pattern. In reality, protein-ligand interactions are more diverse than 
simply plus or minus, and binding is modulated by more than just complementarity. 
Nevertheless, the general outcomes from the complexity model hold true: simpler 
molecules have a higher chance of binding to any target.  
�e trade-off of decreasing molecular complexity is that the maximum potency (either 
a biochemical effect or a biophysical binding event) becomes weaker. Magnitudes of 
biochemical or functional effects are usually expressed in units of compound 
concentration: the concentration at which 50% of positive control activity is observed 
is called the 50% inhibitory concentration, IC50. Binding strengths are usually 
indicated by stating the equilibrium dissociation constant (KD), which coincidentally 
also has the formal unit of compound concentration in the most common case of a 
first-order process (one-step binding). Fragment hits typically have KDs in the 
10-4-10-2 M range (close to the lower detection limit of most instruments), and IC50s 
even lower or zero. Attractive leads typically have (sub-)nanomolar IC50s. �is adds 
the extra step of optimisation of fragment hits to lead-like molecules. �eoretically, 
fragment hit-to-lead optimisation can be accomplished by linking or merging two 
fragment hits binding to different parts of a binding pocket, or by growing one 
fragment hit to fill its binding pocket (Kirsch et al., 2019). Although improving the 
binding affinity of a weak fragment by six orders of magnitude may seem like an 
almost impossible task, the underlying physics of protein-ligand binding can often 
show the way. �e use of biophysical techniques and a structure-based approach to 
lead design are standard practice by now (Renaud et al., 2016). Ligand binding 
energetics were first explored and discussed within the biochemical community by 
Jencks and others in the 1970s (Jencks, 1981, 1975). Two important concepts for 
FBLD are: 1) the relationship between binding affinity and binding energy: the two 
are related not linearly but exponentially via ΔG = -RTln(KD), meaning that small 
changes in binding energy can have larger effects on affinity; and 2) entropic effects 
play a bigger role at lower affinities, meaning that linking or merging two fragment 
hits can increase affinity by more than just the product of parts. Indeed, several 
spectacular fragment linking successes are known (Ichihara et al., 2011). However, it 
is more often the case that fragment linking fails to improve affinity. �is is mostly 
due to the difficulty of designing a linker moiety that can preserve the exact binding 
orientations of the initial two fragments while not itself subtracting from binding 
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affinity. Merging of two fragments that share part of the binding pocket does not suffer 
from these problems, but it does not often happen that two fragments share atoms that 
exactly overlap in the binding pocket (especially when the originating fragment library 
was designed to be diverse). In the end, fragment growing following scaffold 
optimisation appears to be the most popular approach to hit optimisation.  
Fragment hit-to-lead optimisation guided solely by physical parameters has several 
pitfalls. Firstly, a physical binding event does not necessarily correspond to an 
equivalent biochemical activity. Most FBLD practitioners now insist on measuring 
both KD and IC50 for all optimisation compounds. Secondly, practice has shown that 
making hits bigger and more lipophilic will often increase binding affinity and 
biochemical activity regardless of selectivity and specificity (Ferenczy & Keserű, 
2016). To make sure that any addition to a hit is worth the cost of increasing molecular 
weight and lipophilicity, the ligand efficiency (LE) metric was adopted. It is defined 
as the fraction of binding energy contributed by each heavy atom of the ligand on 
average: LE = ΔG/HA. �e number is usually between 0.3 and 0.5 kcal mol-1 for initial 
fragment hits as well as later-stage compounds, and ideally it should not decrease 
during hit-to-lead optimisation. Several variations on LE exist and can be more 
appropriate during some stages of drug development. For example, LE adjusted 
specifically for lipophilicity may become more interesting during later stages when 
drug activity, absorption, distribution, metabolism, and excretion parameters need to 
be optimised simultaneously (Leeson & Springthorpe, 2007).  
Ligands can be modified almost at will (depending on feasibility and tractability of 
synthesis), but their targets (proteins or polynucleotides) are fixed. In early work 
analysing proteins using atomic resolution crystal structures, researchers used 
‘functional groups’ to computationally probe protein surfaces for energetically 
favourable binding sites (Goodford, 1985; Miranker & Karplus, 1991). �ese probes 
are essentially very small fragments, which would be gaseous or liquid in vitro. 
Experimental work used solvents (which are again very small fragments) to probe 
protein surfaces in crystallo (Allen et al., 1996; Mattos & Ringe, 1996). Both of these 
approaches (virtual and ‘wet’) have seen more recent iterations as tools in FBLD, for 
example: FTMap (Kozakov et al., 2015) which probes static protein structures for 
interaction hot spots with small solvent molecules, MDmix (Alvarez-Garcia & Barril, 
2014) which does the same but runs molecular dynamics simulations to incorporate 
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protein flexibility,  and MiniFrags (O’Reilly et al., 2019) that experimentally probe 
crystallised proteins to find new binding (sub)pockets.  
Compared to bluntly screening millions of drug-like molecules, the characterisation 
of fragment-sized molecules, their targets, and their interactions is more precise and 
usually requires more experiments. However, the past twenty years have shown that it 
is worth the efforts (see section 1.1.3), as the field of FBLD has matured from mostly 
academic curiosity into a standard platform in most pharmaceutical companies. �e 
fragment-based approach is used under various circumstances: as back-up hit-finding 
method when HTS fails; to overcome hurdles during lead optimisation; or simply as a 
main approach against certain target classes.  
1.1.2 Fragment detection techniques 
While going smaller increases the chance of binding, it also decreases the chance of 
experimentally detecting such binding. It follows that there is an optimum size of 
screening molecules where promiscuity and affinity balance each other (Hann et al., 
2001). Molecules of this size turn out to be larger than solvents but smaller than HTS 
compounds: fragments. Since fragments are often not active enough to be picked up 
by functional assays, reliable detection of fragment hits depends heavily on the use of 
biophysical techniques, which have seen much method development and 
improvements over the past three decades (Renaud et al., 2016; Coyle & Walser, 2020; 
Erlanson et al., 2019). �e three main techniques used for fragment screening are 
thermal shift assay (TSA), surface plasmon resonance (SPR), and nuclear magnetic 
resonance (NMR). Recently, innovations in infrastructure have made X-ray 
crystallography a fourth attractive screening technique (Erlanson, 2019).  
TSA relies on a change in protein stability upon ligand binding, assessed by the 
temperature at which the protein unfolds (Lo et al., 2004). �e unfolding temperature 
is measured as an increase of fluorescence. �e effect depends on the presence of a 
hydrophobic dye that binds to unfolding protein hydrophobic cores, exhibiting an 
increase in fluorescence efficiency in hydrophobic environments. As it only requires a 
rtPCR machine and consumes very small amounts of protein, it is cheap, quick, and 
easy to execute. TSA results are easy to analyse but have low information content that 
may be over-interpreted. A fundamental drawback of this technique is that the 
observed ligand binding often takes place at temperatures well above room 
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temperature, which could give wrong ideas of binding strengths if overlooked. 
Especially in case of fragments, TSA has a relatively high rate of false negatives and 
artefacts owing to their weak affinity and high concentrations. A popular alternative 
to carrying out a full fragment screen by TSA is to quickly screen a small set of well-
behaved, diverse compounds to assess protein ligandability.  
SPR, NMR, and X-ray crystallography are more expensive and offer lower throughput 
but more detailed and reliable information. SPR relies on a change in refractive index 
close to a solid surface, assessed by the resonance angle of a totally internally reflected 
beam of light at the other side of the surface (Jonsson et al., 1991; Danielson, 2009). 
�us, when protein molecules are covalently linked to a surface, fragments that bind 
will cause a change in refractive index dependent mainly on their concentration and 
molecular weight. SPR measurements are taken in real time by using a flow cell, 
allowing determination of kinetic binding parameters in addition to affinity and 
stoichiometry. SPR is commonly used during fragment screening as well as 
optimisation stages.  
NMR spectroscopy is an extremely versatile technique that relies on changes in the 
local magnetic field of any atomic nucleus with non-zero spin. �e most popular 
application is in imaging of biological tissues. In drug discovery, two types of NMR 
approaches are distinguished: ligand-observed (LO) and protein-observed (PO) NMR 
(Gossert & Jahnke, 2016). �e first measures signals from ligand protons (or, less 
commonly, 19F nuclei), whereas the second measures signals from coherent protein 
protons, 13C nuclei, and 15N nuclei in any permutation of two or three. LO-NMR is 
most often used for fragment screening and hit validation. �ree often-employed 
experiments are saturation transfer difference (STD) (Mayer & Meyer, 1999), water 
ligand-observed via gradient spectroscopy (WaterLOGSY) (Dalvit et al., 2001), and 
transverse relaxation filtering with the Carr-Purcell-Meiboom-Gills (CPMG) sequence 
(Hajduk et al., 1997; Meiboom & Gill, 1958). All three experiments will show a 
change in signal intensity of a ligand when it binds to a protein. In STD and 
WaterLOGSY, protein protons (preferably at shifts smaller than 1 ppm to avoid 
overlap with small molecules) and water protons (around 4.8 ppm) respectively are 
selectively irradiated, after which they transfer some of the energy to the ligand via 
the nuclear Overhauser effect. In the CPMG experiment, protein and protein-
associated protons are filtered out of the spectrum based on their bigger particle size 
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and thus higher transverse relaxation rates compared to unbound small molecules. LO 
methods give information about whether a fragment binds and can also determine 
affinity through titrations and binding site identification through competition 
experiments. LO-NMR can work with protein concentrations as low as 1 µM, but (like 
most NMR experiments) requires large sample volumes (usually 500 µL) which 
results in high protein consumption during screening. Because standard NMR spectra 
are always of high enough resolution to allow observation of chemically unique nuclei, 
a single binding experiment can simultaneously be used for compound identification 
and quality control (sometimes even indicating solubility issues). LO methods are 
limited to the fast-exchange regime of compound binding (usually not stronger than 
0.1-1.0 µM KDs) because of the large excess of ligand over protein. PO methods can 
yield much more detailed information, including direct binding site and binding mode 
identification, detection of slow-exchange binding, and conformational changes. 
Unlike LO-NMR and almost any other biophysical technique, PO experiments rarely 
yield false positives or false negatives. Recent advances in NMR hardware and 
experimental methods have made the simple 2-dimensional heteronuclear single 
quantum coherence experiment viable for screening (Schanda et al., 2005), although 
this still requires large quantities of high-quality, isotope-labelled protein. However, 
PO-NMR is mainly used to obtain high-resolution binding information, especially for 
challenging projects where protein structure and function are impaired by any kind of 
deviation from its standard solvated state (e.g. high temperature, surface 
immobilisation, chemical labelling, or crystallisation).  
X-ray crystallography is the most important technique in structural biology. It relies 
on well-ordered crystals of pure analyte (most often proteins or stable protein 
complexes) to determine their 3-dimensional electronic structures at atomic resolution. 
In drug discovery, it is the preferred approach for validating and guiding early ligand 
optimisation, provided that high-resolution structures can be obtained. Some research 
groups use crystallography as their main fragment screening platform. However, this 
is only possible if high quality crystals (i.e. well-diffracting, resistant and permeable 
to solvated screening compounds) can be grown reliably. �e main drawback of 
crystallography as a fragment screening technique is the high concentrations of ligand 
needed, which can lead to false positives and does not distinguish between strong and 
weak binders. Furthermore, crystal packing can sometimes occlude possible binding 
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sites, which can sometimes but not always be overcome by co-crystallising ligands 
and proteins instead of soaking ligands into crystals.  
Many other biophysical techniques exist that can measure the interactions of proteins 
and ligands, some of which are sporadically used for screening but are not part of the 
standard screening platform of most research groups. In particular, isothermal titration 
calorimetry (ITC) is a technique that gives detailed information on fundamental 
binding parameters including changes in enthalpy and entropy separately. Like NMR, 
ITC experiments are carried out label-free and in solution. �e high material 
requirements and low throughput make ITC unamenable to screening, but it is used 
during optimisation to test hypotheses about protein-ligand binding energetics based 
on structural information. Lastly, mass spectrometry (MS) is a standard (bio)physical 
technique that can be adapted to carry out screening. Depending on the required 
throughput, MS can give detailed information about protein-ligand complexes, 
including ligand identity, stoichiometry, approximate binding site, and affinity. An 
example of covalent fragment screening by MS will be discussed in the next section.  
1.1.3 FBLD in practice 
One of the first traditional examples of fragment-based lead generation used NMR to 
identify, optimise, and finally link two fragments binding close to each other on the 
same protein (Shuker et al., 1996). It is a remarkable example of successful fragment 
linking, of which unfortunately not many others exist. Against the background of the 
more theoretical works on the interactions between proteins and fragment-sized 
molecules in the 1980s and 1990s (discussed earlier), this work stood out as the first 
demonstration of how to develop weak hits (in this case, KDs of 2 µM and 800 µM) 
into a high-affinity (19 nM) lead compound. �e two hits bound to two adjacent sites 
on the FK506-binding protein (FKBP), an enzyme that plays an important role in T-
cell activation. After slightly improving the affinity of the weaker fragment hit from 
800 to 100 µM, a 3D binding model of the two adjacent fragments was constructed 
from PO-NMR data. �is model suggested which vectors could be used to link the two 
fragments, and the length of the linker was then quickly optimised experimentally to 
produce the 19 nM linked lead compound. �e work presents a combination of earlier 
fragment-based ideas put into practice in a way that is now recognised as the standard 
FBLD approach.  
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Although FBLD is mainly a way to generate early-stage lead candidates, many FBLD 
practitioners proudly mention fragment-derived leads that were progressed through 
the clinic onto the market. As of 2020, four such fragment-based drugs exist: 
vemurafenib (Bollag et al., 2012), pexidartinib (Zhang et al., 2013), venetoclax 
(Souers et al., 2013), and erdafitinib (Murray et al., 2019) (Figure 1.1). Venetoclax 
stands out as an example of unusual chemistry and a difficult target. It inhibits the 
functional interaction of its family of target proteins, the prosurvival B-cell 
CLL/lymphoma 2 (BCL-2) family, with other proteins to cause tumour cell death. 
Inhibition of protein-protein interactions (PPIs) is seen as challenging because PPI 
surfaces have few pocket-like features or other handles for small molecules. �e 
development of venetoclax depended heavily on structure-based methods including 
the identification of two weakly binding, non-competitive fragments by PO-NMR 
(Petros et al., 2006) and the discovery of a new protein crystal form during lead 
optimisation (Souers et al., 2013).  
 
Figure 1.1. All current FDA-approved drugs with a fragment-based origin. The moiety 
corresponding to the initial fragment hit is indicated.  
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Nowadays the field of FBLD is a well-established technology with standard 
approaches and practices as described. Scientists from public as well as private 
organisations continue to innovate and find new ways of using fragments. Recent 
examples include screening for enzyme activators (Darby et al., 2017; Tautermann et 
al., 2019), new ways of fragment library design and synthesis (Keserű et al., 2016; 
Firth & O’Brien, 2018), and the use of fragments that form specific covalent bonds 
with their targets (Parker & Pratt, 2020; Keeley et al., 2020). Covalent fragments can 
be divided into two groups: intrinsically reactive fragments and fragments that contain 
an inducible covalent linker. Fragments in the first group are mild electrophiles that 
can react with nucleophilic protein residues (C, K, and activated S, T, Y, H, or E). �e 
reactivities of such fragments are chosen so that covalent bond formation will mostly 
occur when the fragment is favourably bound and oriented, avoiding false-positive 
hits from non-specific reactions. Protein nucleophilic reaction parameters are well 
characterised and can also be used to screen electrophilic fragments in silico (Scarpino 
et al., 2018). �e second group of reactive fragments are molecules that contain a non-
reactive, variable fragment moiety linked to a reactive functional group that can be 
‘switched on’. Such inducible reactive groups have been popular tools in chemical 
biology for decades and include alkyne/azide click chemistry (Patterson et al., 2014; 
Parker & Pratt, 2020) and photoreactive probes (Murale et al., 2016). Chemical groups 
such as benzophenone and diazirine are sensitive to ultraviolet light, so that upon 
exposure they will convert into highly reactive intermediates attacking anything in 
their immediate vicinity. �us, if irradiated while bound, a chemical probe containing 
such a photoreactive group will crosslink to its target protein. �e resulting complex 
can then be detected by MS. �is approach can identify and quantify probe-target 
interactions in complex mixtures or even in vivo. Combining this approach with 
fragments seems counterintuitive since fragments are not very specific probes, but it 
was recently shown that photoreactive fragments can actually have clearly selective 
target profiles in human cells (Parker et al., 2017; Wang et al., 2019). Using 
proteomics methods, the researchers showed that a small set of fragment probes 
formed bona fide interactions with many proteins in human cell culture, each fragment 
having a different selectivity profile. �ey could also determine approximate binding 
sites for some protein-fragment pairs, show functional modulation of two high-
occupancy protein-fragment pairs, and apply their methodology to find adipogenesis-
promoting target-fragment pairs by phenotypic screening. �e work is a remarkable 
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example of using fragments in a phenotypic setting for target discovery, since FBLD 
has so far been an overwhelmingly target- and structure-based venture.  
�is thesis, too, presents a fragment-based approach towards inhibitors of a defined 
target using biophysical, structure-based methods. However, the target in this case is 
not a single biomolecule, but a molecular machine consisting of many different parts 
which help to perform a single function. �is introduces a phenotypic aspect to the 
project that requires novel ways of thinking and problem-solving. �e structural and 
functional characteristics of this molecular machine will be described in the next 
section.  
1.2 �e replisome 
�e biomolecular target of an FBLD campaign is usually predefined and is usually a 
single polypeptide or -nucleotide. Non-fragment-based campaigns, requiring less or 
no atomic-resolution structural information, may also simply target a whole cell-level 
or organism-level phenotypic outcome. �e target of this project lies somewhere in 
between the two, as it is a set of proteins that have different structures and functions 
yet work together to produce a single measurable outcome. �e nuances will be 
described in this section.  
�e target of this project is the replisome of E. coli. ‘Replisome’ is a loose term for 
the body of proteins that are directly involved in replication of DNA. Unlike other 
molecular machines, e.g. ribosomes or proteasomes, replisomes are not stable 
complexes, but sets of dynamic and transiently interacting subcomplexes. Genetically, 
replisomes can be classed as either eukaryotic/archaeal or prokaryotic/viral. Although 
there is no evolutionary conservation between the two classes, most replisome subunit 
functions and even some structures are highly similar. �e basic DNA replication 
mechanism consists of three steps: initiation, elongation, and termination.  
�e initiation step is a separate process, mediated by a different set of proteins called 
the primosome in bacteria or the pre-replicative complex in eukaryotes, that melts the 
origin of replication and loads a replisome on each template strand.  
�e elongation step replicates the whole template, producing one copy, and is 
mediated by the replisome and various accessory proteins such as gyrases and ligases. 
In vivo, additional essential factors are those that remove blocks on DNA, repair 
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lesions, and restart replisomes when they stall. Both template strands are replicated 
simultaneously. DNA duplexes are anti-parallel, and all known replicative 
polymerases can only extend polynucleotides in the 5ʹ-3ʹ direction. It follows that 
synthesis of the lagging strand happens discontinuously in small steps as the 
replication fork moves forward. �is mechanism may seem unnecessarily complex 
compared to simply replicating two leading strands, yet all life replicates dsDNA this 
way. It requires dedicated priming, distributing, ligating, and stabilising proteins to 
guide the process, but the extra work is preferable to leaving one template strand 
exposed as ssDNA for long periods of time. An alternative solution would be to use a 
reverse polymerase, capable of elongating in the 3ʹ-5ʹ direction. However, while 
examples of such enzymes exist (Jackman et al., 2012), the absence of a processive 
reverse polymerase for templated lagging strand elongation implies that there are 
serious disadvantages that prevent evolution of such mechanisms (Ballanco & 
Mansfield, 2011). �e two possible mechanisms of 3ʹ-5ʹ polymerisation are or were 
not efficient enough for use as an alternative to discontinuous lagging strand 
replication: nucleophilic attack of a 5ʹ-triphosphate primer end by an incoming 3ʹ-OH  
would stall in case of spontaneous triphosphate hydrolysis or of mismatch repair, and 
nucleophilic attack of an incoming 3ʹ-triphosphate by a 5ʹ-OH primer end would 
require additional machinery to synthesise and maintain sufficient levels of 3ʹ-NTPs 
that are much less stable than 5ʹ-NTPs. Furthermore, other (unknown) causes may 
have contributed to a situation in which 5ʹ-3ʹ polymerisation was the only viable 
mechanism for very early life forms, leaving only this mechanism available for 
inheritance (founder effect). �us, discontinuous lagging strand synthesis is now the 
only known mechanism of dsDNA replication.  
�e termination step involves halting and disassembly of the replisome, then filling 
any small remaining gaps and disentangling the terminal region by mechanisms that 
are not yet fully elucidated but involve topoisomerases and recombination repair 
proteins. �us, the replisome itself is dedicated solely to the simple task of elongating 
primers on a dsDNA template. Replisomes are the fastest and most accurate 
polymerase systems known, with typical synthesis rates of 500-1,000 bases per second 
and error rates of one mismatch per 108-1010 base pairs. How the E. coli replisome 
achieves this will now be described.  
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1.2.1 Characteristics of the whole replisome 
�ere are many PPIs within the replisome, with the clamp loader complex being the 
central hub that keeps the polymerases associated with the replication fork (Figure 
1.2). Several proteins are stably complexed during replication, but most interactions 
between replisome subunits are weak, transient, and stochastic. For example, E. coli 
primase has a binding affinity of approximately 1-5 µM for helicase (Oakley et al., 
2005) and slightly stronger than 1 µM for ssDNA (Swart & Griep, 1995). �us, 
replisome activity is mainly dependent on local subunit concentrations. �e enzymatic 
activities of many subunits are dependent on other replisome components, so that their 
activities while isolated from the replisome are much lower to the point of becoming 
inactive. �is characteristic is also important during replication as a way of keeping 
the replisome together. For example, the leading strand polymerase can randomly 
pause and lag behind the replication fork, at which point the helicase becomes less 
active, giving the polymerase time to catch up (Graham et al., 2017). As a result, the 
replisome is a flexible and robust molecular machine with the highest efficiency of any 
nucleic acid replication system.  
 
    
Figure 1.2. Schematic representation (left) of a snapshot of an active replisome at a 
replication fork (leading strand DNA template: red, lagging strand DNA template: grey, RNA 
primers: blue). All components are also listed in Table 1-1. Right: PPIs within the replisome. 




1.2.2 �e polymerase holoenzyme 
�e E. coli replisome consists of a central large protein complex called the polymerase 
III holoenzyme (pol III HE). �ere are several additional proteins that are essential 
parts of the replisome but are not part of this complex. Each single subunit of pol III 
HE is functional on its own but is extremely inefficient compared to most other 
enzymes with identical functions. Only when the whole replisome comes together, 
they become efficient. A functional pol III HE consists of 3 different complexes: the 
clamp loader containing seven subunits of which five unique, the pol III core 
containing three unique subunits, and the β sliding clamp (Table 1-1). �ese three 
subcomplexes are true structural complexes, while PPIs between them and with other 
replisome subunits are transient. �e pol III HE is called the ‘holoenzyme’ based on 
early in vitro biochemical experiments using an ssDNA template (Hurwitz & Wickner, 
1974; McHenry & Kornberg, 1977), without considerations for its native template or 
structural arrangements. It is the minimal set of proteins needed to achieve the typical 
high speed and processivity of the replisome, however without the helicase complex 
the pol III HE can only synthesise a leading strand. �e functions and structures of 









name Function Stoichiometry 
Pol III core    1-3 
 dnaE α (pol III) polymerase 1 




 holE θ unknown 1 
Clamp loader    1 




 holA δ structural 1 




 holC χ structural 1 




Sliding clamp dnaN β 





   1 
 dnaB DnaB helicase 1 hexamer 
 dnaG primase primase 2-3 
Helicase 
loader 
dnaC DnaC helicase loader 1 hexamer 
SSB ssb SSB ssDNA binding many tetramers 
 
1.2.2.1 Pol III core 
Pol III core is the heterotrimer of α, ε, θ (Figure 1.3). �e α subunit is the replicative 
polymerase. Its catalytic core has a classic right hand-shaped structure (Lamers et al., 
2006). While the structure of the ~200 amino acid (aa) C-terminus is not known at 
atomic resolution, its sequence, its structure of a bacterial homologue (Liu, Lin et al., 
2013), and medium-resolution cryo-EM structure (Fernandez-Leiro et al., 2015) 
indicate that it is composed of a flexible β-binding peptide followed by an 
oligonucleotide-binding (OB) domain. �is C-terminus is essential for α to gain its 
boosts in speed (~1 kb/s (Bloom et al., 1997)) and processivity through binding to β 
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and τ. In addition, private observations show that even as a monomer, full-length α is 
faster than its catalytic core alone, possibly because the OB fold increases the affinity 
of α for ssDNA. �e α N-terminal polymerase/histidinol phosphatase (PHP) domain 
may have been a proofreading exonuclease domain earlier in evolution (Stano et al., 
2006; Barros et al., 2013). Its current function is suggested by some to be 
pyrophosphatase (Fabio Lapenta et al., 2016), though that hypothesis was challenged 
by others earlier (Lamers et al., 2006).  
In many Gram-positive bacteria, the dnaE gene product is also an essential polymerase 
of the replisome, but another polymerase (PolC) is responsible for the greater part of 
DNA synthesis (Dervyn et al., 2001; Sanders et al., 2010; Rannou et al., 2013).  
 
Figure 1.3. Model of the pol III core in complex with DNA. Subunit α (surface representation) 
consists of an N-terminal PHP domain (beige), a polymerase domain (yellow) that wraps 
around dsDNA (red template strand, grey nascent strand), and an OB domain (beige). 
Subunit ε (orange secondary structure representation) consists of an N-terminal exonuclease 
domain and a long, partially disordered C-terminal peptide that binds to both α and β. 
Subunit θ (pink secondary structure representation) binds to ε. Model compiled from a cryo-
EM structure of an α-ε-β-DNA complex (5fkv (Fernandez-Leiro et al., 2015)) aligned to an 
NMR model of the ε-θ complex (2xy8 (Schmitz & Bonvin, 2011)).  
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�e actual proofreading in the pol III core is carried out by ε. �is 3ʹ-5ʹ exonuclease 
has an N-terminal catalytic domain dependent on two bivalent cations (Hamdan et al., 
2002), and a C-terminal helix that binds the α PHP domain (Bressanin et al., 2009) 
(Figure 1.3). Between the N- and C-terminus, a long flexible linker peptide contains a 
β-binding peptide like α does. Interestingly, the crystal structure of the ε exonuclease 
domain (Hamdan et al., 2002) shows density for two nucleotides at sites where it is 
hard to imagine a DNA strand could be positioned based on the overall structure of β-
pol III core (Fernandez-Leiro et al., 2015). More recently it was shown that, in fact, 
these densities overlap almost perfectly with the position of a mismatched DNA strand 
in the pol III core complex (Fernandez-Leiro et al., 2017). In addition to its 
proofreading function, ε also has a stabilising effect on α (Jergic et al., 2013).  
�e small, non-essential θ subunit has a large binding interface to ε so that ε sits in 
between α and θ in the pol III core (Schmitz & Bonvin, 2011) (Figure 1.3). Other than 
a slight stabilising effect (Taft-Benz & Schaaper, 2004), it may have functions outside 
the replisome (Dietrich et al., 2014).  
�ere are no known inhibitors of pol III core. Recently, the natural product nargenicin 
has been reported to bind to and inhibit α (Painter et al., 2015) based on analyses of 
mutations in the S. aureus homologue. However, we have been unable to show binding 
of nargenicin to E. coli α by thermal shift analysis, nor consistent inhibition in our 
polymerisation assay. Additionally, the proposed binding region of nargenicin is based 
on a single aa mutation (S765L) which has however been reported earlier to have a 
stabilising effect as a rescue of dnaQ deletion (Lancy et al., 1989). �erefore, it is 
possible that nargenicin has a destabilising effect on pol III HE that is not caused by 
binding to α.  
Within the pol III core, small molecule-mediated inhibition of either of the two active 
sites is possible. However, it might be difficult to develop fragments into specific 
binders as these sites are intrinsically non-specific to nucleotides. Disruption of PPIs 
within pol III core or between pol III core and the sliding clamp or the clamp loader 
might be more promising.  
1.2.2.2 Clamp loader 
Loading and unloading of the sliding clamp on the lagging strand template-primer 
duplex happens approximately 2,000 times per replication cycle, since the E. coli 
30 
 
genomic DNA is ~4.7 Mbp and the average Okazaki fragment is ~1 kb. �e clamp 
loader is a heteropentameric ring consisting of δʹτ3δ (in counterclockwise order when 
N-termini point towards the viewer) (Figure 1.4). �e three subunits have very similar 
folds, despite low sequence similarity. Any number of τ subunits can be replaced by 
γ, the gene product of an alternative dnaX transcript that encodes only the first three 
out of five protein domains (Flower & McHenry, 1990; Tsuchihashi & Kornberg, 
1990; Blinkova et al., 1993). Domains I and II are responsible for ATPase activity, 
and domain III is the oligomerisation domain. In contrast to most related ATPases, 
domains I of δʹ and γ/τ contain zinc-binding C4 motifs of unknown function. Domain I 
of δ contains a β-recognition motif. Domains IV and V of τ bind to replisome subunits 
DnaB and α, respectively. �erefore, clamp loaders containing only γ can load and 
unload sliding clamps but cannot form part of the replisome. �ere is enough space 
inside the clamp loader ring to bind a primed DNA template, which can enter the ring 
laterally through a gap between δʹ and δ. �e structure of the open clamp loader ring 
(Simonetta et al., 2009) resembles that of other AAA+ family proteins, with ATP-
binding sequence motifs present in the τ N-terminal domains so that there are three 
functional ATP-binding sites on the interfaces between the five subunits. A possible 
mechanism of action for clamp loading is the following series of events: 1) ATP binds, 
2) the clamp loader recognises and opens β2, 3) ssDNA binding near a primed site 
induces conformational change reminiscent of screwing from the flat symmetrical apo 
structure (Jeruzalmi, O’Donnell et al., 2001) to one where the τ and δ subunits shift 
out of the plane, their NTDs sliding along the primed DNA backbone (Figure 1.4), and 
4) ATP is hydrolysed, β2 closes and the clamp loader is released. Clamp unloading 
does not require ATP hydrolysis, and can be catalysed by free δ (Leu et al., 2000) or 





Figure 1.4. Model of the ATP- and DNA-bound state of the E. coli clamp loader in complex 
with an open sliding clamp, representing step 3) described in the text. The γ complex (surface 
representation, different shades of green for different gene products) wraps around the DNA 
template strand (grey) primed with a 10-base DNA primer (blue), placing an open β2 dimer 
(cyan and blue) slightly ahead of the primer. Model compiled from crystal structures of the 
γ complex with bound DNA, ψ N-terminal peptide, and ADP-BeF3 (3gli (Simonetta et al., 
2009)), δ domain I in complex with β (1jql (Jeruzalmi, Yurieva et al., 2001)), the closed β2 
dimer (4k3s (Yin et al., 2013)), and the χψ complex (3sxu (Marceau et al., 2011)). 
A second, more important function of the clamp loader is its role as a central 
distributive interaction hub. �e τ subunit C-terminus can bind both helicase and α 
(Dallmann, 2000). Although observations of multimeric pol III core have been made 
long ago (McHenry, 1982), and structures of the τ pol III binding CTD are known 
(Fernandez-Leiro et al., 2015; Liu, Lin et al., 2013), no structures of pol III HE or any 
combination of two of three major bacterial replisome subcomplexes (pol III core, 
clamp loader, and helicase) have been observed. �is is not surprising, since pol III 
HE must be highly dynamic, many PPIs are transient depending on which function is 
being carried out, and most interaction domains are connected through flexible linkers.  
An additional distributive function of the clamp loader is mediated by the non-
essential subunits χ and ψ. �e ψ subunit serves as a linker between the clamp loader 
and χ. Its N-terminal peptide (aa 2-28) binds the pentameric clamp loader ring with 
nanomolar affinity by inducing a β-strand alignment with the γ C-terminus (Simonetta 
et al., 2009), and C-terminal side of ψ has a large interaction surface with χ (Figure 
1.4). Opposite this interaction surface, χ has a binding site for the highly conserved 
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SSB C-terminal peptide (Marceau et al., 2011). �is SSB C-terminus is a recognition 
site for many DNA-binding proteins (Shereda et al., 2008), including one other 
component of the replisome, primase (Naue et al., 2013). �is suggests that χ and ψ 
enable the clamp loader to recognise primed lagging strand template sites.  
1.2.2.3 Sliding clamp 
Sliding clamps have similar function and shape in all organisms, despite the lack of 
sequence similarity (Indiani & O’Donnell, 2006). Homodimers (in case of e.g. E. coli) 
or -trimers (in case of e.g. humans) form a doughnut shape around dsDNA with a non-
specific positively charged inner surface. Sliding clamps serve as anchor points for 
many different proteins that operate on DNA. E. coli β monomers have sub-nanomolar 
affinity for each other, so that even without DNA, β is mostly dimeric in solution. Its 
binding half-life on dsDNA has been reported to be between 1-2 h (Yao et al., 1996; 
Leu et al., 2000).  
�e β2 dimer of E. coli has one binding pocket per monomer, to which replisome 
proteins ε, δ, α, and various other proteins such as ligase and non-replicative 
polymerases can bind. It is also the target site of a few reported replication inhibitors, 
like the auto-inhibitory bacterial gene product SocB (Aakre et al., 2013), the bacterial 
natural product griselimycin (Kling et al., 2015), and several fragments recently 
identified by crystallographic screening (Yin et al., 2014) and virtual screening 
(Pandey et al., 2017). �e sliding clamp is clearly a good antibacterial target, though 
not a novel one.  
1.2.3 Helicase complex 
�e DnaB replicative helicase sets the pace of the replisome and is one of only two 
replisome components that do not exchange throughout a normal replication cycle (the 
other being the leading strand sliding clamp). During replication initiation, DnaB 
forms part of the primosome complex together with the helicase loader DnaC, the 
primase DnaG, and other proteins. During elongation, DnaB defines the location of 
the replication fork, forming transient complexes with the clamp loader and primase 
(Figure 1.5).  
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1.2.3.1 DnaB helicase 
�e DnaB helicase is a homohexamer with moderate sequence conservation between 
bacteria. �ere are no high-resolution structures of the E. coli helicase, but several 
crystal structures from Gram-positive homologues are known. �e inactive structure 
is a flat ring with six fold symmetry of the CTDs but threefold symmetry of the NTDs 
(Wang et al., 2008; San Martin et al., 1995). Its CTDs interact with τ (Gao & 
McHenry, 2001) and the helicase loader (Liu, Eliason et al., 2013), while its NTDs 
interact with primase (Bailey et al., 2007) and the replication initiation factor DnaA 
(Seitz et al., 2000). Helicase moves along the lagging strand template (5ʹ-3ʹ direction), 
using ATP hydrolysis to displace the leading strand template with its CTDs. Its active 
form has a spiral conformation (Itsathitphaisarn et al., 2012; Arias-Palomo et al., 
2013).  
1.2.3.2 DnaC helicase loader 
�e helicase loader, DnaC in E. coli, belongs to the AAA+ family and has a 
mechanism of action similar to that of the clamp loader. However, DnaC is a monomer 
in its inactive solution form (Galletto et al., 2004) and a homohexamer in its active, 
ATP- and DnaB-bound form. Helicase loading has two different mechanisms 
depending on phylum: loading of a preassembled helicase hexamer by one protein 
(e.g. E. coli DnaC (Arias-Palomo et al., 2019)) or loading and assembly of six 
monomers by two proteins (e.g. Bacillus subtilis DnaB/DnaI (Velten et al., 2003)). In 
the first mechanism, the DnaBC complex twists into a spiral conformation, opening a 
crack through which ssDNA can diffuse into the central channel. DNA-binding then 
triggers ATP hydrolysis. Some researchers have observed that loader release in E. coli 
requires primase or RNA primer binding (Makowska-Grzyska & Kaguni, 2010). 
DnaC ATP hydrolysis thus perhaps only locks the complex on ssDNA but does not 





Figure 1.5. Model of the E. coli DnaB helicase (blue) in complex with DnaC helicase loader 
(brown), DnaG primase (purple & pink), and ssDNA (surface representation, grey). The 
DnaBC-ssDNA model (6qem (Arias-Palomo et al., 2019)) is in the closed state after DnaC 
ATP hydrolysis. Primase models based on structures of its three domains: helicase-binding 
(2haj (Oakley et al., 2005)), RNA polymerase (1dde (Keck et al., 2000)), and zinc-binding 
domain (homology model derived from 1d0q (Pan & Wigley, 2000)). Relative positioning of 
the helicase NTD and primase HBD based on the homologous complex of Geobacillus 
stearothermophilus DnaB and DnaG HBD (2r6c (Bailey et al., 2007)).  
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1.2.3.3 DnaG primase 
�e helicase NTDs interact with DnaG primase, so that a maximum of three primase 
molecules can be bound to the helicase at any one time (Figure 1.5). Primase consists 
of three flexibly linked domains that have different functions to increase the overall 
activity of the enzyme. Primase binds to helicase through a helical hairpin structure of 
its C-terminal helicase-binding domain (HBD) (Su et al., 2006). In addition, the HBD 
has an SSB peptide-binding site on the surface of its small, α-helical hydrophobic core 
sub-domain. �e helical hairpin of some homologues, including E. coli (Oakley et al., 
2005), is mostly observed as ‘extended’ with respect to the hydrophobic core, forming 
a single ~30 aa α-helix. Other homologues show a break in the middle of this helix, 
adopting a conformation that is likely unable to bind helicase (Catazaro et al., 2017). 
Possibly, there is a common mechanism by which binding of an effector switches the 
conformation from active to inactive or vice versa. �e middle, large catalytic domain, 
the RNA polymerase domain (RPD), synthesises a short (10-12 nucleotides in E. coli) 
RNA primer. �e open, solvent-accessible catalytic site is formed by two subdomains: 
the conserved topoisomerase-primase (Toprim) domain coordinates two or three Mg2+ 
ions (Pansegrau & Lanka, 1992; Godson et al., 2000; Aravind, 1998), while the the 
other subdomain presumably discriminates the sugar and provides a basic ridge for 
template binding. �e primase N-terminal zinc-binding domain (ZBD) is required for 
recognition of priming initiation sites, which are different for each organism (3ʹ-GTC 
for E. coli (Yoda & Okazaki, 1991)). After primer synthesis, primase remains attached 
to the primed site, presumably to prevent primer degradation by other proteins 
(Yuzhakov et al., 1999), until the sliding clamp and pol III core are loaded onto the 
primer. Since both primase and the clamp loader bind the SSB C-terminal peptide, 
competition for SSB binding is a likely mechanism of securely replacing primase by 
sliding clamp on the RNA primer. Interestingly, the T7 primase and helicase are part 
of the same polypeptide, causing the lagging strand template to trail behind the 
helicase, creating a loop until the primer is released (Hamdan et al., 2009). It is likely 
that the same ‘trombone’ mechanism (Alberts et al., 1983) also occurs in E. coli 
(Tougu & Marians, 1996).  
Many compounds inhibit helicases and primases, but most of these are either non-
specific or cytotoxic. Examples are the natural product myricetin which inhibits DnaB 
helicase (Griep et al., 2007), and the endogenous signalling nucleotide ppGpp which 
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inhibits primase (Maciąg et al., 2010; Rymer et al., 2012). High-throughput screening 
against Gram-positive helicases has yielded a specific inhibitor (Aiello et al., 2009; Li 
et al., 2013), yet without any reported cellular activity. Recently, fragment screens by 
NMR identified fragments binding to an allosteric site on the T7 primase catalytic 
domain (Ilic et al., 2016) and to the SSB peptide-binding site of the E. coli HBD 
(Chilingaryan et al., 2018).  
1.2.4 Single-stranded DNA-binding protein and other proteins 
Single-stranded DNA-binding protein (SSB) functions as a general protecting agent 
of ssDNA. As this is also an essential part of chromosome replication, and SSB is 
required in vitro, it is mentioned here as part of the replisome. It is a homotetrameric 
protein with an oligomerising and DNA-binding NTD and a long (65 aa) disordered 
C-terminal peptide (Savvides et al., 2004). �e conserved six ultimate C-terminal 
residues (DDDIPF) serve as a tether for many different DNA-binding proteins, 
including primase and χ. In the absence of bound ssDNA, this C-terminal tail is in fast 
exchange with the DNA binding sites (Shishmarev et al., 2014). Small molecule 
mimics of this C-terminal peptide have been reported to bind to the E. coli SSB 
interaction partner ExoI (Lu et al., 2010), but none have been developed as therapeutic 
agents.  
Other proteins that are essential to bacterial DNA replication, but do not interact with 
the described replisome, are: certain ligases, nucleases and polymerases to correct 
template strand errors, remove RNA primers etc.; initiation (DnaA (Shimizu et al., 
2016)) and termination (Tus (Mulcair et al., 2006)) proteins; proteins involved in 
stabilisation or reloading of stalled replisomes (McGlynn & Guy, 2008; Yeeles et al., 
2013); and topoisomerases, which relieve torsional strain in the DNA double helix 
generated by helicase. �e latter class of enzymes are the targets of the classic 
quinolone and aminocoumarin classes of antibiotics, against which resistance is 
known.  
1.3 Antibiotic targets 
As described in the previous section, there are few proteins within the replisome that 
have been proven to be good targets for antibiotics, even though all but one were found 
to be essential gene products (Baba et al., 2006). �e best-characterised antibiotic 
agent targeting the replisome is griselimycin, a natural product that targets the sliding 
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clamp. However, it should be noted that the sliding clamp serves as a general anchor 
point for many different proteins that operate on DNA, and thus also has functions 
outside the replisome.  
Historically, natural products have helped us identify the best antibiotic targets for 
therapeutic intervention. �e most important antibiotic target classes against which 
effective, natural product-derived antibiotics exist nowadays are ribosomes (targeted 
by e.g. tetracyclines, aminoglycosides), RNA polymerases (rifampicin), gyrases 
(aminocoumarins), tRNA synthetases, and various enzymes involved in cell wall 
synthesis (β-lactams) (Silver, 2013). Other, non-protein targets are cell wall 
peptidoglycans (vancomycin) and the Gram-negative outer membrane (polymyxins). 
Several of these have been targeted by different antibiotics independently, indicating 
that the functions of these targets are both essential and susceptible to interference. In 
some cases, target location (intracellular, periplasmic, or extracellular) also 
contributes to susceptibility. Intracellular targets are more difficult to reach because of 
the barely permeable bacterial outer membrane and peptidoglycan layers and because 
of efficient drug efflux pumps that were poorly characterised until recently. �ese two 
barriers are difficult to overcome especially when developing small molecule 
antibiotics de novo, noted by e.g. researchers at AstraZeneca (Tommasi et al., 2015). 
Furthermore, in case of bacteria-derived natural product antibiotics (e.g. from 
Streptomycete screening), the ability of the producing organism to resist its own 
antibiotics is an additional factor affecting targetability. In a similar but more general 
sense, this may also be part of the reason why the replisome is not a major antibiotic 
target: DNA replication is too important and too similar in all forms of life to enable 
efficient and selective inhibition.  
Most antibiotic natural products evolved to be effective in their own micro-
environments, which is a very different type of use compared to human therapeutic 
interventions (Davies, 2006). Less than a century after the discovery of the first 
antibiotic, humans are now facing widespread resistance to classic antibiotics. �ese 
resistance mechanisms evolved in response to overuse in humans and livestock. Since 
this problem arose in human environments, it is less likely that natural products will 
be able to solve it for a second time. Our list of requirements for ‘good’ antibiotics 
(broad spectrum, high efficacy, high tolerance, ease of use) is not shared by the micro-
organisms from which we derived most first-in-class antibiotics. Especially the 
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requirement that our antibiotics be effective against a broad spectrum of bacterial 
species limits the list of possible targets, as was found by researchers at GSK (among 
others) in the early 2000s (Payne et al., 2007). As a result of these strict product 
requirements, discovery and development of antibiotics has been very slow over the 
past several decades. �e most recent novel antibacterial compound class that is 
currently on the market (oxazolidinones) was discovered in the early 1980s (Slee et 
al., 1987), although its target (the ribosome) is not new.  
New drugs are clearly needed to fight bacterial infections and antibiotics resistance. 
However, new approaches are needed not only in drug discovery but also in the clinic 
and at the economic and political level. Novel antibiotics (even natural product-
derived ones) are within reach, but they are unlikely to be as powerful as the antibiotics 
of the previous century. Furthermore, it is likely that there are more good antibiotic 
targets to be discovered rationally, without the help of natural products (for example 
β-lactamases). Narrow spectrum antibiotics, which only work against a few bacterial 
species, should be used only against infections with those species, requiring routine 
diagnostics in and outside the hospital. Furthermore, to prevent the emergence of pan-
resistant bacterial strains, effective antibiotics should be used correctly and sparingly. 
To promote research and development of such products, different economic incentives 
are needed that do not depend on sales by volume (Roope et al., 2019). Thus, discovery 
of novel antibiotics is only a small part of the solution to the current antibiotics 
resistance problem. Recent reports of public organisations such as the World Health 
Organization and many national government commissions including that of the United 
Kingdom (O’Neill, 2016) describe these strategic problems and solutions in more 
detail. However small the part of novel antibiotics research may be, it is clearly 
essential and still full of opportunities regarding discovery of new antibiotics against 
known targets as well as of new targets.  
1.4 Aims of the project 
In vivo replisome activity is influenced by many factors including chaperones, 
signalling molecules, and DNA damage. In fact, most information about how 
replisomes work comes from in vitro experiments with vastly simplified conditions. 
�e E. coli replisome is one of few that have been successfully reconstituted in vitro 
(other examples are the replication machinery of bacteriophage T7 (Lee & Richardson, 
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2011; Gao et al., 2019), Bacillus subtilis (Sanders et al., 2010), and Saccharomyces 
cerevisiae (Georgescu et al., 2014)). Comparisons with measurable in vivo parameters 
show that an in vitro replisome is a good, if difficult and complex, model system. 
Because of its essential function, the replisome is a good antibiotic target in principle 
(Baba et al., 2006), and the availability of a reconstituted system makes it attractive 
for target discovery and validation. �e single function of the replisome provides a 
good readout for screening assays. However, the fact that it is made up of no fewer 
than 28 proteins (of which 13 unique) gives it the characteristics of a phenotypic 
system requiring target identification.  
�is thesis will describe efforts to validate and deconvolute fragment screening results 
against the reconstituted E. coli replisome. �e fragment-based approach and the 
replisome are an exciting combination because of the novelty of screening against such 








2 Structural and functional characterisation of hits from a 
fragment screen against a bacterial replisome 
Preface 
�e author of this manuscript gratefully acknowledges the contributions of Dr. J.A.L. 
Howard (McGlynn group) to results presented in this chapter, i.e. the screening and 
initial confirmation of the York fragment library in the replisome assay described in 
section 2.1. �e author also gratefully acknowledges the contributions of Dr. S.W.M. 
Tanley (Hubbard group) to results presented in this chapter, i.e. the production of α 
and the testing of hits and analogues for inhibition of α.  
2.1 Introduction 
�e bacterial replisome is a collection of protein complexes that together replicate 
double-stranded DNA (dsDNA) (described in detail in section 1.2). �e McGlynn 
group at the University of York is able to reconstitute a functional version of the 
replisome in vitro. Dr. J.A.L. Howard of the McGlynn group conducted an initial 
screen of the York fragment library for fragments that inhibited replisome activity. 
�e work described in this chapter follows up on the results of this initial screen, which 
will first be summarised here.  
�e York fragment library was designed and maintained by the Hubbard group and 
contained 1,004 fragments that were selected from the commercial Maybridge Ro3 
collection (see introduction section 1.1.1). Criteria for selection were to maximise 
chemical diversity based on molecular fingerprints (Hassan et al., 2006) and 3D shape 
(Sauer & Schwarz, 2003). At the time of use, the library was formatted as 200 mM 
stocks in dimethylsulfoxide (DMSO) that had been kept in dark, ambient conditions 
for approximately two years.  
�e replisome against which the fragment library was screened consisted of thirteen 
different essential subunits: Pol III core complex (αεθ), clamp loader complex 
(τδδʹψχ), sliding clamp (β), primase, helicase, helicase loader, and single-stranded 
DNA-binding protein (SSB). All proteins were produced from native E. coli K-12-
derived genes cloned into bacterial overexpression vectors, except for the helicase 
loader. �e helicase loader gene contained a mutation in codon 176 (known as 
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dnaC810 (Xu & Marians, 2000; Sandler et al., 1996)) that increases the activity of the 
enzyme, making the presence of other initiation factors (essential in vivo) no longer 
necessary.  
�is version of the replisome will replicate a dsDNA template but requires the template 
to have a pre-formed fork and leading strand primer because of the absence of 
initiation and priming factors (see introduction section 1.2). Here, an artificial template 
was used that satisfies these requirements: a circular, M13-based dsDNA plasmid 
containing a nick with single-stranded overhang, similar to M13 replicative form II 
(Pratt & Erdahl, 1968; Lin & Pratt, 1972). �e overhang allows the loading of helicase, 
and the nick provides a primer for leading strand elongation. �is template facilitates 
‘rolling circle’ replication, which in the absence of control proteins will generate a 
linear leading strand of many times the length of the original circle. �is generated 
leading strand also serves as the lagging strand template. �e process is drawn 
schematically in Figure 2.1. �us, once assembled, the replisome functions in vitro 
like it does during the in vivo elongation phase.  
�e complexity of the reaction makes it inefficient, and only a fraction of available 
template plasmids will contain stable, active replisomes. To still reliably quantify 
reaction products, a small amount of α-32P-labelled deoxycytidine triphosphate 
(dCTP) substrate is added to the reactions. �e P-32 nuclide undergoes β-decay into 
stable S-32 and high-energy electrons, providing a sensitive read-out that does not add 





Figure 2.1. The M13 replicative form II template facilitates rolling circle replication, yielding 
a single leading strand (red) and a distribution of shorter lagging strand Okazaki fragments 
(green). The reaction used during screening contains all subunits listed in Table 1-1 and 
elongation proceeds as described in section 1.2. Briefly, three activities contribute to the 
observed final products: 1) the DnaB helicase is loaded onto the M13 template by DnaC 
helicase loader. 2a) processive leading strand elongation by the pol III core, kept in place by 
the β sliding clamp that was loaded by the τ complex (τc) clamp loader. 2b) discontinuous 
lagging strand synthesis initiated by de novo RNA primer synthesis by the DnaG primase. The 
β sliding clamp is loaded onto each new primer-template duplex by the τc clamp loader which 
needs SSB to locate these new primers. The clamp loader also acts as an interaction hub, 
keeping the helicase and the two polymerases together.  
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Screening was carried out in tube-based format over the course of several months. 
Details of the screening procedure can be found in section 7.2. Briefly, together with 
each set of 10 fragments (0.5 mM) as singletons, a positive control (DMSO) and a 
negative control (omitting Pol III core) were run to determine maximum and 
background signals within each set. A control fragment inhibitor of the sliding clamp, 
4-(p-fluorophenyl)benzoic acid, identified from literature (Yin et al., 2014), was also 
tested each day. A plot of the control fragment response over the course of the 
screening campaign shows that there was no drift over time (Figure 2.2), indicating 
that assay conditions, enzymes, template, and reagents were stable over time.  
�e average replication in the presence of control fragment (75% ±9) was also used as 
a hit cut-off criterium. �is yielded an initial hit set of 120 fragments (12%), a hit rate 
typical for fragment screening against enzymes. One likely cause of false-positive 
replisome inhibition is fragment binding to the template non-specifically. �erefore, 
the initial 120 hits were tested for DNA intercalation in a topoisomerase I assay which 
relaxes negatively supercoiled dsDNA. �is identified 21 fragments that partially or 
completely inhibited supercoil relaxation, leaving 99 fragments as ‘true’ replisome 
inhibitors (Figure 2.3). Interestingly, many among the top inhibitors were found to be 
DNA intercalators.  
 
Figure 2.2. Inhibition of replication by the control fragment inhibitor at regular intervals 
during the screening of the 1,004-fragment library. The average replication in presence of the 
control fragment inhibitor was 75% ±9. No trends or anomalies in the drift of measured 























Figure 2.3. Chart of 120 initial fragment hits sorted by activity. The 21 DNA-intercalating hits 
are coloured red. A hit cut-off of 75% replication was used based on the control fragment 
inhibitor. Interestingly, most of the top 10-20 inhibitors are intercalators.  
Eliminating intercalators leaves 20 hits that inhibit the replisome 50% or more, and 79 
that inhibit the replisome between 25-49%. �ese top 20 hits, and five other, randomly 
chosen hits, were selected for confirmation and subsequent assays against individual 
replisome components (structures of these 25 fragments are given in Appendix A). 
For confirmation, the hits were tested against the whole replisome again at three 
different concentrations (20, 100, 500 µM) to check for concentration-dependent 
activity. Out of 25 tested hits, three did not show concentration-dependent inhibition 
and indeed less inhibition at the highest concentration than was initially observed 
during screening. Comparing the 0.5 mM data points from screening and confirmation 
assays (Figure 2.4), 14 out of 25 hits showed similar activities (within error), 10 
showed less activity after confirmation, and one hit (MB63) did not show inhibition 






Figure 2.4. Comparison of hit activities against the whole replisome observed during 
screening and subsequent confirmation. Most hit activities could be reproduced.  
Finally, these 25 selected hits were tested against various individual replisome 
components, namely: pol III subunit α, pol III holoenzyme (αεθτδδʹψχβ), helicase, 
helicase + helicase loader, and helicase + primase (it must be noted that some of these 
assays, especially helicase and primase, were quite insensitive and therefore gave 
ambiguous results for some compounds). Most hits inhibited multiple of these assays, 
but four were active against only one replisome component. For example, hit MB19 
inhibits the whole replisome and pol III holoenzyme, but not any other component 
(Figure 2.5). Interestingly, one hit (MB7) inhibited the whole replisome but not any 

























































































Figure 2.5. Activities of five hits in the whole replisome assay and in assays of different 
replisome components. Four hits are active against the whole replisome and one component 
of it, while hit MB7 is only active against the whole replisome.  
 
2.2 Results 
�e screening results presented in the Introduction section were available at the start 
of this project. �e rest of this chapter describes results from follow-up experiments 
aimed at identifying the most interesting hit compounds for which to investigate their 
mechanisms of action.  
2.2.1 Compound quality controls 
Every screening technique has different susceptibilities to yielding false-positive and 
-negative data, and biochemical assays are well-known to be sensitive to false-positive 
interfering compounds (Baell & Holloway, 2010). Furthermore, compound 
aggregation or precipitation are common causes of artefacts and false-positives in 
biochemical screening (McGovern et al., 2003). As noted in section 2.1, the York 
library stocks used for screening were rather old. Organic compounds dissolved at 
high concentrations can precipitate or degrade over time, sometimes accelerated by 
water, oxygen, light, or high temperature (Keserű et al., 2016). �erefore, the 25 
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solubility. Compound integrity was assessed by proton nuclear magnetic resonance 
(NMR), using samples containing one fragment each at 0.5 mM in phosphate-buffered 
saline. Compound solubility was assessed by checking for precipitation during sample 
preparation, as well as by NMR (insoluble or aggregating compounds will show 
unexpected peak intensities, chemical shifts, or line widths in their 1D proton spectra). 
�e WaterLOGSY experiment (used in section 2.2.3) can identify aggregators too, 
since the signal strength is dependent on the rotational correlation time of observed 
species (Dalvit et al., 2006). Although the NMR buffer (sodium phosphate) was quite 
different from the replisome assay buffer (HEPES, nucleotides, BSA), compound 
solubilities were also monitored during the second set of confirmation assays (Figure 
2.7) and were found to match the observations made during NMR sample preparations.  
One compound contained precipitate in its DMSO stock (MB9). Six compounds 
(MB1, 2, 4, 14, 16, 20) precipitated upon dilution, four out of which also showed little 
to no signal in their spectra. �ree further compounds (MB8, 17, 18) showed 
differences in their spectra compared to their references, which were recorded when 
the library stocks were first prepared. For example, the spectrum of MB18 compared 
to its reference spectrum showed a decrease in intensities of some peaks with 
simultaneous increase in total number of peaks, indicating the conversion of part of 
the original sample into one or multiple new chemical species (Figure 2.6).  
It was decided to exclude these potential false positives from all further experiments, 
as there was a considerable number of hits that passed the control experiments and 
none were structurally related to those that failed. Interestingly, most problematic 
compounds in this screen cluster towards the top-ranked inhibitory compounds. Since 
half-maximum inhibitory concentrations (IC50s) of fragments are typically in the 0.1-
10 mM range, the highest inhibition that could be reasonably expected at a screening 
concentration of 0.5 mM would be roughly 80%. �is trend perhaps serves as a 





Figure 2.6. Quality control of fragment hit MB18. The initial 1H NMR spectrum (blue) contains 
all expected peaks with only minor impurities. The spectrum of the compound stock after 
screening (red) contains many additional peaks, suggesting compound degradation. Inset 
shows a small region of the spectra in more detail. The initial chemical structure is shown.  
 
2.2.2 Confirmation of screening hits 
Proton NMR analysis of compounds can identify significant changes to the 
compounds themselves, but not the presence of any minor or non-organic 
contaminants (e.g. metal ions) in DMSO stocks. To further assess whether these hits 
are true-positives, all initial hits (Figure 2.4) were repurchased, their stocks were made 
fresh and their quality was checked by NMR again. Reactions were repeated 
independently with both old and new compound stocks. While results for the control 
inhibitor fragment could be reproduced, results for many initial hits could not be 
reproduced (Figure 2.7). Several attempts were made, but no obvious causes were 
identified. �e real causes might be related to subtleties in compound or protein 
handling, stock preparation, or work-up methods of replication reaction products. On 
the other hand, repetitions of the same experiment can also be useful as an indicator 
of hit robustness. For example, like the control fragment, MB25 behaved reproducibly 
in all experiments. Several other fragments with reproducible inhibition (MB1, 16, 17) 
had been confirmed as insoluble compounds from both old and new compound stocks. 
�e only fragment hits that could be reconfirmed as potentially promising replisome 







single replisome component (Figure 2.5). A fifth fragment (MB7) inhibited the 
replisome but was inactive against any of the six tested components. Although this 
hinted at the exciting possibility of binding to a type of interface site that is only 
formed when the whole replisome is active, MB7 was deprioritised because of non-
reproducibility. Since the activities of MB25 and MB33 in different replisome 
component assays (Figure 2.5) suggest that each inhibits a specific subunit, these hits 
were marked as the most interesting hits to follow up.  
 
 
Figure 2.7. Comparison of hit activities between the original screen confirmation data 
(confirmation I, see Figure 2.4), independent confirmation reactions using the same compound 
stocks (confirmation II), and independent confirmation reactions using fresh compound stocks. 
Many hit activities could not be reproduced.  
Next, the selected fragment hits shown in Figure 2.5 were assessed for concentration-
dependent replisome inhibition. Reaction products (leading and lagging strands) were 
also separated on gel to check for hints of inhibition mechanisms. As expected, MB7 
and MB19 did not appear to inhibit replication even at the highest tested concentration 
(5 mM). MB99 did show up to 48% inhibition, but still none at the concentration used 
for screening. MB25 and MB33 showed concentration-dependent inhibition up to 
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just over 1 mM (Figure 2.8). Interestingly, these two fragments show different effects 
on reaction product profiles. MB33 only appears to affect the overall amount of 
reaction products. MB25 additionally causes an increase in average size of lagging 
strand Okazaki fragment distributions (that is, the peak retention factor decreases; see 
bottom half Figure 2.8). �is suggests that MB25, in addition to inhibiting the 
polymerase (Figure 2.5), is modulating a distributive component of the replisome 
(clamp loader, primase, SSB). �e effect is most reminiscent of a loss of primase 
function: indeed, when titrating primase into the whole-replisome reaction, the 
opposite effect of decreasing Okazaki fragment size can be observed (Tougu et al., 
1994).  
MB33 seemed to be a reproducible hit targeting the polymerase subunit α, but 
unfortunately it was later found to be a likely false positive by others in the Hubbard 
group (discussed in section 2.2.4). �erefore, MB25 remained as the sole confirmed 
hit with reproducible activity, with MB99 showing signs of weak inhibitory activity 




Figure 2.8. Titration data and fitted curves for replisome inhibition by MB25 and MB33. IC50 
values calculated from fit are shown. Inhibition was measured by counting pixel intensities 
per gel lane (below) as a fraction of the total intensity of the positive control lane. Below, 
representative phosphor gel images of each titration are shown. Leading and lagging strands 
are separated based on size (see Figure 2.1). Peak positions based on lane pixel intensities 
are indicated by red bars. The average lagging strand size increases with addition of MB25 




2.2.3 How MB25 and MB99 inhibit the replisome 
�e question whether primase inhibition can explain the effect MB25 has on the 
replisome was further investigated, since MB25 was initially indicated as an α 
inhibitor. Literature was searched for small molecule inhibitors of E. coli primase, but 
the only promising candidate was the endogenous signalling molecule guanosine 3ʹ,5ʹ-
bispyrophosphate (ppGpp). �is nucleotide analogue is produced by bacteria including 
E. coli in response to stress signals, and inhibits many cellular processes including 
transcription and replication (Srivatsan & Wang, 2008). It inhibits primase enzymatic 
activity (Maciąg et al., 2010), most probably by binding to its active site (Rymer et 
al., 2012). When titrated into the replisome reaction, ppGpp indeed inhibited DNA 
replication (IC50 1.4 mM), but surprisingly did not affect Okazaki fragment size 
(Figure 2.9). Possibly, ppGpp inhibits another nucleotide-binding replisome 
component with greater efficacy, so that the effect on primase becomes negligible and 
does not appear after gel electrophoresis.  
As an alternative more specific probe for primase function, it was hypothesised that a 
non-hydrolysable ribonucleotide analogue could be used. Guanine is the second base 
in each E. coli RNA primer and as such is needed for primer synthesis initiation (see 
introduction section 1.2.3.3). Guanosine 5ʹ-(α,β-methyleno)triphosphate (GpCpp or 
GMPCPP) should specifically inhibit primer initiation, allowing the initiation complex 
to form but not to react. �e only other replisome component known to use GTP is 
helicase, however it hydrolyses the β,γ phosphoester bond and can use ATP with 
similar efficiency (Roychowdhury et al., 2009). GpCpp inhibited the replisome with 
an IC50 of >2 mM (in the presence of GTP at 200 µM) (Figure 2.9). Crucially, in 
addition to inhibiting total reaction products, it also caused an increase in Okazaki 
fragment size. �e gel images further suggest that the total amount of Okazaki 
fragments decreases faster than the total amount of leading strands. However, separate 
quantification of each band shows only slightly faster inhibition of Okazaki fragment 
synthesis at lower GpCpp concentrations (Figure 2.9, right graph). �is is expected 
since leading and lagging strand synthesis are coupled processes. It remains possible 
that GpCpp also inhibits helicase, since helicase can use both ATP and GTP, but in 
this assay it likely uses mostly ATP because it is present at high (2 mM) 
concentrations. Moreover, it is possible, though unknown, that helicase could 
hydrolyse the β,γ-phosphoester bond of GpCpp functionally. �erefore, the most 
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likely explanation for the overall inhibitory effect on both leading and lagging strand 
synthesis by MB25 and GpCpp is that the two processes are coupled, so that inhibiting 
one also slows down the other. �e similar effects of GpCpp and MB25 on the 
replisome are consistent with inhibition of primase function.  
To further confirm the hypothesis that MB25 inhibits the replisome by acting on 
primase, NMR was used to detect their physical interaction. Recombinantly produced 
active primase was incubated with excess MB25 and NMR spectra were recorded 
using the ligand-observed WaterLOGSY method (Dalvit et al., 2000). �is method 
differentiates binding from non-binding ligands based on a change in sign of water-
ligand magnetisation transfer efficiency. �e magnitude of the ligand signals depends 
on several experimental parameters, but bound ligands generally show positive peaks 
while non-binding molecules show negative signals due to differences in their 
rotational correlation times. Figure 2.10 (bottom, blue spectrum) shows that MB25 
binds to the primase full-length (FL) protein. Additionally, a sample of one of the 
isolated primase domains, the active site-containing RNA polymerase domain (RPD), 
was also available. Interestingly, when incubated with only the primase RPD, MB25 
does not show binding (middle, red spectrum), suggesting that it binds to one of the 
non-enzymatic domains of primase. Primase has two other domains with accessory 
functions (see introduction section 1.2.3.3). Inhibition of either of these functions is 
consistent with overall inhibition of primer synthesis activity. It has been shown 
previously that inhibition of the C-terminal domain (a protein-protein interaction 
domain) causes an increase in Okazaki fragment size (Tougu et al., 1994). �e next 
steps for elaboration of MB25 should be to identify its binding site and/or mechanism 











































      
 
Figure 2.9. Representative gel phosphor image of ppGpp and GpCpp titrations. Leading and 
lagging strands are separated based on size (see Figure 2.1). Peak positions based on lane 
pixel intensities are indicated by red bars. The average lagging strand size increases with 
addition of GpCpp. The average inhibition is shown for each band (leading or lagging strands) 





































Figure 2.10. WaterLOGSY spectra of MB25 (1 mM) together with: full-length primase (blue, 
bottom), primase RNA polymerase domain (red, middle), or buffer only (green, top). MB25 
seems to bind to full-length primase but not the RPD alone. Ligand peaks are highlighted, and 
the peak at 7.11 ppm is shown as detailed overlay. Other peaks originate from buffer 
components: HEPES, DTT, DSS, DMSO, and glycerol. The structure of MB25 is shown.  
Finally, since MB99 was identified as another possible primase inhibitor (Figure 2.5), 
this compound was also tested for primase binding. MB99 indeed appears to bind full-
length primase. Furthermore, it also appears to bind to the RPD, although weakly. �e 
measured inhibitory activity and the WaterLOGSY peak intensities thus appear to 
agree with each other to indicate that MB99 is a weaker binder and inhibitor than 
MB25. It would be interesting to see whether MB99 also causes an increase in Okazaki 
fragment size. Unfortunately, the solubility of this fragment was too low to allow 
titration up to >50% inhibition. MB99 was later used for primase follow-up 







Figure 2.11. WaterLOGSY spectra of MB99 (0.5 mM) together with: full-length primase (blue, 
bottom), primase RNA polymerase domain (red, middle), or buffer only (green, top). MB99 
seems to bind to both full-length primase and to the RPD alone. Some ligand peaks are 
highlighted, other peaks fall under solvent peaks. The peaks around 7.3 ppm are shown as 
detailed overlay. Other peaks originate from buffer components: Tris, HEPES, DTT, DSS, 
DMSO, and glycerol. The structure of MB99 is shown.  
 
2.2.4 Analysis of structural motifs within the replisome fragment hit set 
Even though the York fragment library was designed with maximum structural 
diversity in mind, it contains subsets of compounds that contain identical or very 
similar substructures. �is is helpful when wanting to quickly assess whether a hit is 
attractive for follow-up. For each of the five selected hits (Figure 2.5), the screening 
library was searched for substructure matches. Any matching analogue that was also 
a non-intercalating hit was subjected to quality control by NMR as described earlier.  
Table 2-1 lists the analogues that either passed quality control or were not active. 
Several insights can be gained from these comparisons to aid in prioritising hits for 
follow-up experiments. MB19 could not be confirmed as a hit earlier, and this appears 
to agree with the screening data: the same compound was present as a sample made 
up from its potassium salt form which did not inhibit the replisome. �e initial hit 





�e other unconfirmed hit, MB7, did not have sufficiently close analogues to draw any 
conclusions. However, the identification of its methylcinnoline analogue as a strong 
DNA intercalator (see Figure 2.3) was seen as a warning.  
MB99 was found to inhibit the replisome but only at higher concentrations (see section 
2.2.2). Two close analogues could be identified in the screening data, but only one was 
marked as a hit. �ere are no obvious differences between the three structures that 
could explain the results. �is hit could be interesting to follow up on, but would need 
careful investigation of its exact binding mode. A co-crystal structure would be 
preferable in order to identify possible growth vectors for structure-activity 
relationships (SAR) series. �e target of MB99, the primase RPD, has been 
crystallised before (Keck et al., 2000). Co-crystallisation and soaking experiments 
with the RPD and MB99 were conducted later (see section 4.3.2).  
MB33 has only two analogues within the library despite its simple structure. 
Interestingly, replacing the carboxylic acid by a primary amine (polar opposites in 
terms of functional groups) abolishes its activity, suggesting that a negative charge 
might be important for inhibition of its target (likely polymerase subunit α, Figure 
2.5). Since this scaffold is common, up to ten close analogues preserving the 
carboxylate group could be purchased and tested against polymerase α by Dr. S.W.M. 
Tanley (Hubbard group). Surprisingly, none of the analogues were active. 
Furthermore, the same compound MB33, purchased from two other suppliers than 
Maybridge, appeared to have no activity against the replisome nor against α. �e most 
likely explanation for the initial activity of MB33 is the presence of a contaminant, 
either at low concentrations or of inorganic nature to escape detection by 1H NMR. 
Polymerases are Mg2+-dependent and are known to be sensitive to different cations at 
varying concentrations (Miyaki et al., 1977; Hermann et al., 2013). Alternatively, it is 
possible that the contaminant was in fact a chelating agent used during compound 
purification to remove such ionic impurities. Although a chelator at low concentrations 
is unlikely to inhibit polymerase in the presence of 10 mM of Mg2+, it could interfere 
with other replisome components coordinating Zn2+ (primase, clamp loader) (Mendes 
et al., 2011). �erefore, this hit was deprioritised.  
MB25 is an uncommon scaffold with few close analogues within the library. Still, 
three out of seven distant analogues (either preserving the thiophene 2-carboxylate 
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scaffold or the benzo[c]thiophene scaffold) were active against the replisome. Since 
there is nothing to suggest that MB25 was a false-positive hit, and it is the most potent 
hit for which a target could be suggested, it is an attractive hit to move forward.  
Table 2-1. Screening data for selected hit analogues. Rank indicates amount of inhibition, 
rank 1 being the most inhibitory fragment. The first 100 fragments are hits.  
MB19   
Structure Rank 
Proportion 
replication (±SE) Comment 
 
292 0.87 (0.03) Salt form 
 
597 0.97 (0.03)  
 
MB7   
Structure Rank 
Proportion 
replication (±SE) Comment 
 
616 0.98 (0.08)  
 
2 0.00 (0.01) DNA intercalator 
 
MB33   
Structure Rank 
Proportion 
replication (±SE) Comment 
 
542 0.95 (0.13)  
 
464 0.93 (0.06)  






































Table 2-1 (continued) 
MB99   
Structure Rank 
Proportion 
replication (±SE) Comment 
 
45 0.57 (0.13)  
 
667 1.00 (0.11)  
 
MB25   
Structure Rank 
Proportion 
replication (±SE) Comment 
 
50 0.59 (0.04)  
 
656 0.99 (0.07)  
 
94 0.72 (0.04)  
 
735 1.03 (0.12)  
 
276 0.85 (0.07)  
 
83 0.70 (0.07) No QC 
 















































2.3  Conclusion 
All experiments described in this chapter were conducted with the purpose of hit 
confirmation and prioritisation. Out of the top 25 hits from the original screen, 10 
compounds did not pass simple quality control tests due to compound degradation or 
insolubility. Out of the 15 remaining hits, only 6 reproducibly inhibited the replisome. 
Out of these 6 confirmed hits, 2 (MB25 and MB33) had previously shown targeted 
inhibition of a single replisome component. �ese two were then titrated into the 
replisome assay to determine their IC50s, where it was discovered that MB25 has a 
remarkable effect on replication products. MB25 caused a concentration-dependent 
increase in lagging strand size distributions, consistent with inhibition of the primase 
subunit of the replisome. While MB25 was not marked as a primase inhibitor during 
the replisome component assays, it was shown by NMR experiments that MB25 (as 
well as MB99 which did show early signs of primase component inhibition) physically 
binds to primase. Furthermore, the effects of MB25 on the whole replisome reaction 
were similar to those of GpCpp, a tool compound designed to specifically inhibit 
primer synthesis initiation. �erefore, primase was identified as an interesting target 
with the fragment inhibitors MB25 and possibly MB99 as starting points for more 








3 Finding the binding site of a primase fragment hit using 
molecular dynamics simulations 
3.1 Introduction 
Chapter 2 described the identification of an inhibitor (MB25) from fragment screen 
against the replisome that was shown to bind to primase (see section 2.2.3). �e effect 
of MB25 on replisome activity was consistent with inhibition of the primase subunit, 
but crystallographic efforts failed to find a binding site for MB25 on the primase RPD. 
While a mechanism of primase inhibition by binding to the active site domain was the 
most straightforward hypothesis to test, it is not the only possible mechanism that 
would explain the observed effects of this fragment. �e RPD of bacterial primases is 
preceded by a zinc-binding domain (ZBD) and followed by a helicase-binding domain 
(HBD) (Frick & Richardson, 2001) (Figure 3.1), which modulate the RNA polymerase 
activity of primase. As discussed in section 1.2.3.3, the ZBD controls initiation of 
primer synthesis by facilitating the formation of the initiation complex (Corn et al., 
2005). It contains a CHC2 motif capable of coordinating a zinc ion that most likely 
stabilises a β sheet fold that can recognise specific template trinucleotide sequences 
(Larson et al., 2010) (Figure 3.2). �e HBD controls the activity of primase by 
targeting it to the replication fork through interaction with the replicative helicase 
(Tougu et al., 1994). It is entirely α-helical, containing a small globular domain with 
hydrophobic core and a long C-terminal helix hairpin that is involved in helicase 
binding (Figure 3.2). Inhibition of ZBD-DNA interactions or of HBD-helicase 
interactions is therefore also expected to decrease the RNA polymerase activity of 
primase in the context of the replisome.  
 
Figure 3.1. Schematic representation of primase domains. The conserved zinc-binding CHC2 
and magnesium-binding E-DxD motifs are indicated. Domain boundaries are given in residue 
indices.  
High-resolution structural information for full-length primase is currently not 
available and would be difficult to obtain, because the flexibility of the protein makes 
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it unamenable to crystallisation, and the size of the protein is above the practical limit 
for assignment of NMR resonances. To find out whether MB25 binds to either of these 
non-catalytic domains, each would have to be produced separately. Structural 
information for the isolated domains is available: a crystal structure of the ZBD of 
Geobacillus stearothermophilus primase (50% sequence identity to the E. coli DnaG 
ZBD) (Pan & Wigley, 2000), and a crystal structure (Oakley et al., 2005), solution 
NMR structure (Su et al., 2006), and solution NMR backbone assignments (Naue et 
al., 2013) for the E. coli primase HBD (Figure 3.2). As these structures were already 
available, it was hypothesised that in silico predictions could help prioritise production 
of and biophysical experiments with one of the two domains and so facilitate an overall 
more efficient workflow.  
 
 
Figure 3.2. Structures of the G. stearothermophilus primase ZBD (Pan & Wigley, 2000) (top) 
and the E. coli HBD (Su et al., 2006) (bottom). The ZBD zinc ion and coordinating CHC2 
residues are shown.  
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Computational tools are widely used in structure-based drug design. �e most popular 
methods are docking of small molecules into protein binding pockets as a way of 
virtual (pre-)screening and assessing structure-activity relationships (SAR), and 
molecular dynamics (MD) simulations of protein-ligand systems as a way of assessing 
protein dynamic behaviour and ligand binding kinetics and thermodynamics (Śledź & 
Caflisch, 2018). Docking can be done very efficiently by relying on general 
assumptions about protein rigidity and solvent effects, whereas MD simulations are 
low-throughput but relatively unbiased and can give much more information. 
Continuous hardware and software developments over the last decade or two have 
made MD simulations for large systems more accessible and more reliable (Harvey & 
De Fabritiis, 2012; Bottaro & Lindorff-Larsen, 2018). Forcefields prescribing the 
behaviour of atoms in standard biomolecular systems such as proteins and 
polynucleotides have become highly accurate. However, one should remember that 
these parameter sets are based on historical experimental observations, and can 
sometimes still be wrong (Auffinger et al., 2007) or incomplete (Pinheiro et al., 2017). 
Simulation results can be used to formulate a hypothesis which should then be tested 
experimentally.  
Here, MD simulations were used to predict which primase domain is most likely to 
contain the binding pocket for MB25, taking advantage of the fact that simulations can 
be run without requiring any prior information about possible binding pockets. �e 
expected result would be a clear preference of MB25 for either the ZBD or the HBD 
of primase, and identification of the protein residues involved in forming the binding 
pocket. �ese predictions were then tested by looking for protein chemical shift 
perturbations (CSPs) by NMR.  
3.2 MD simulation results 
3.2.1 Model preparations 
Two systems were prepared for simulations using Amber (Case et al., 2014). Each 
system contained water, NaCl, one molecule of MB25 and one molecule of either ZBD 
or HBD.  
�e published NMR structure of the entire HBD (547-581) was used (Su et al., 2006). 
No model of the entire ZBD (2-101) is available, so a homology model was prepared. 
�ere are two known structures of homologous ZBDs: a crystal structure of the G. 
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stearothermophilus primase ZBD (Pan & Wigley, 2000), and a crystal structure of the 
Aquifex aeolicus primase ZBD linked to its RPD (Corn et al., 2005). Sequence 
alignment of these two ZBD templates to the E. coli target (Figure 3.3) shows that the 
G. stearothermophilus ZBD has the highest sequence identity with the target (50%) 
and contains no alignment gaps.  
 
 
Figure 3.3. Alignment of E. coli primase ZBD with homologues of which structures are known. 
The G. stearothermophilus model 1d0q was chosen as a template for homology modelling of 
the E. coli ZBD based on higher sequence identity compared to A. aeolicus.  
An E. coli homology model based on this template (chain A from PDB 1d0q (Pan & 
Wigley, 2000)) was generated using the homology modelling tool in the MOE 
software package. �e model has an average Cα root-mean-square deviation (rmsd) 
from the template of 0.47 Å after protonation and energy minimisation. Its QMEAN 
Z-score (Benkert et al., 2011) is -1.16, suggesting that the model is reasonably similar 
to experimental protein structures in the same size range in terms of torsion, solvation, 
and atom and residue interaction potentials.  
While forcefield parameters for biological macromolecules are generally accurate, 
those for other types including small organic molecules are less well-described. A 
thorough and accurate description of MB25 electrostatic potentials was deemed 
necessary here in order to best predict the weak interactions between the fragment and 
its protein binding site. �erefore, partial atomic charges for MB25 with deprotonated 
carboxylate group were calculated using ab initio quantum mechanical methods, then 
normalised and converted into Amber-compatible atom types.  
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Eight different systems were prepared for parallel simulation runs: four for each 
protein domain. Each system contained one protein molecule and one ligand molecule 
in different orientations at least 5 Å away from each other.  
3.2.2 Simulation results 
MD simulations were performed for 500 ns per system, i.e. a total of 2 μs per protein 
domain. Proteins were quite dynamic, with an average backbone rmsd of 2.1 Å for the 
ZBD and 3.7 Å for the HBD after realignment. �e N-terminal globular part of the 
HBD (residues 450-529), which contains a hydrophobic core, is less dynamic than the 
long C-terminal helix hairpin (residues 530-579). �is is revealed by analysis of the 
backbone rmsd for each part separately, after aligning all residues or only the globular 
domain. Alignment of the globular domain only results in a decrease of the rmsd for 
that domain from 3.5 Å to 2.6 Å, while the helix hairpin backbone rmsd for residues 
547-579 increases from 4.3 Å to 10.0 Å. �is flexibility is most likely real, and 
important for helicase binding or unbinding, since some primase HBD homologues 
adopt helicase-unbound conformations in which the helix is broken in the region 
correlating to residue 547 (Syson et al., 2005; Bailey et al., 2007; Catazaro et al., 
2017).  
Analysis of simulations focussed on the movements of MB25 relative to the protein 
in each 500 ns trajectory separately. During most trajectories MB25 prefers to stay 
near a limited set of residues, which is different for each ZBD run but the same for 
each HBD run (Table 3-1). Each set forms a shallow binding site. �e binding sites of 
the ZBD cover four different sides of the domain (Figure 3.4A). �e binding site of 




Table 3-1. Proximity of MB25 to protein residues as a fraction of total trajectory time (top 10 
most occurring for each simulation run). Residues in bold appear in the top 10 of more than 
one run.  
ZBD 
#1 #2 #3 #4 
M92 1.00 R4 0.74 L14 0.35 T51 0.64 
L22 1.00 I5 0.71 N11 0.35 N35 0.63 
T17 0.98 V97 0.66 R7 0.34 H60 0.55 
H93 0.96 V86 0.58 N69 0.27 F58 0.54 
D18 0.96 P6 0.56 A15 0.23 N53 0.51 
D21 0.96 E87 0.53 Q57 0.23 K56 0.50 
L89 0.88 P98 0.51 F82 0.18 Y59 0.47 
R16 0.76 V83 0.48 I10 0.18 V52 0.46 
R26 0.41 F99 0.48 R4 0.13 F62 0.37 
L74 0.04 F9 0.48 K56 0.12 K34 0.19 
        
HBD 
#1 #2 #3 #4 
R452 0.98 R452 0.76 R452 0.64 R452 0.61 
I455 0.98 T515 0.72 L519 0.61 L519 0.52 
T515 0.97 I455 0.69 T515 0.41 T515 0.49 
G481 0.94 L484 0.68 I455 0.37 I455 0.41 
L519 0.93 L519 0.66 G481 0.35 L484 0.40 
L484 0.92 G481 0.63 L484 0.35 G481 0.37 
M451 0.87 M451 0.60 M451 0.32 M451 0.36 
P480 0.60 P480 0.44 W522 0.30 N512 0.35 
L516 0.38 N512 0.43 I453 0.28 L516 0.34 
N512 0.31 L516 0.36 G456 0.25 Y507 0.25 
 
 
Figure 3.4. MB25 interacts with different surfaces of the ZBD during the four different 
simulation runs (run 1: blue, run 2: red, run 3: green, run 4: orange) (A), but only one site on 




Protein-ligand proximity analysis indicates whether MB25 is engaging the protein but 
does not say anything about the quality of interactions. Hydrogen bonds often 
contribute significantly to the binding energy of ligands, especially in case of 
fragments. �erefore, H bond analysis was performed. MB25 has two H bond 
acceptors, which are part of the anionic carboxylate. Table 3-2 shows that MB25 
accepts H bonds mainly from cationic arginine side chains, which is also a favourable 
ionic interaction. During each run, the most frequent H bond donors are residues that 
were also identified in the proximity analysis (Table 3-1). However, the fraction of 
simulation frames during which protein-ligand H bonds are present is smaller than 
during which protein and ligand are near each other. �is could be in part due to the 
stricter distance restraints for H bonds (<3.5 Å) compared to those used for the 
proximity analysis (<4 Å), and to the fact that fewer ligand atoms can participate in 
H bonds. It is also possible that different types of interactions contribute more to 
binding. MB25 has hydrophobic aliphatic and aromatic features that can interact 
favourably with hydrophobic protein sidechains, and an aromatic sulfur atom that can 
interact favourably with carbonyl oxygens (Zhang et al., 2015). �e interaction sites 
identified in simulations do contain clusters of hydrophobic/aromatic side chains likely 
to contribute to MB25 binding, especially ZBD residues I5, V97, and F9 in simulation 
#2 (e.g. Figure 3.5A), and HBD residues I455, T515, L519, and L484 in all HBD 
simulations (e.g. Figure 3.5B). A search for intermolecular sulfur-oxygen bonds did 





Table 3-2. Protein hydrogen bond donors to MB25, by fraction of simulation time during 
which at least one protein-ligand H bond is present. 
ZBD 
#1 #2 #3 #4 
R16 Nη2 0.09 R4 Nη2 0.47 N69 Nδ2 0.11 N35 Nδ2 0.23 
R16 Nη1 0.07 R Nε 0.34 R7 Nη1 0.04 K34 Nζ 0.08 
R16 Nε 0.06 R4 N 0.14 R7 Nε 0.04 K56 Nζ 0.03 
R26 Nη1 0.02 R7 Nη1 0.03 R4 Nη2 0.02 K30 Nζ 0.03 
R26 Nη2 0.02 G3 N 0.03 R7 Nη2 0.01 N53 Nδ2 0.01 
  R7 Nε 0.02     
  R4 Nη1 0.02     
  A2 N 0.02     
  I5 N 0.01     
        
HBD 
#1 #2 #3 #4 
R452 Nη1 0.12 R452 Nε 0.10 T450 Oγ1 0.16 R452 Nη2 0.23 
R452 Nε 0.12 R452 Nη2 0.10 M451 N 0.15 R452 Nε 0.21 
R452 Nη2 0.11 R452 Nη1 0.07 R452 Nε 0.08 R452 Nη1 0.06 
N512 Nδ2 0.04 N512 Nδ2 0.05 R452 N 0.06 R448 Nε 0.03 
R452 N 0.03 R568 Nη1 0.02 R452 Nη1 0.06 K528 Nζ 0.01 
K518 Nζ 0.03 T450 Oγ1 0.01 R452 Nη2 0.06   




Figure 3.5. Example snapshots of MB25 binding modes with the ZBD (A) or HBD (B), 
showing hydrogen bonds (yellow dashed lines) and hydrophobic residues.  
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While MB25 interacted with the ZBD for large fractions of time in each simulation 
run, and the interactions seem arguably favourable from a physicochemical 
perspective, the four runs did not converge to any common binding site or set of 
residues. Furthermore, it is difficult to imagine any of the interaction sites being 
functionally relevant, except the site identified in run #4 which is the DNA interaction 
surface containing F58 (important for initiation site recognition (Larson et al., 2010)) 
and conserved residues N35, K56, and F62. Interestingly, ionic and H bond 
interactions by the nearby K34 and K56 with the MB25 carboxylate are not frequently 
observed, with N35 being the major H bond donor. �e pharmacophore of this site 
seems to be suboptimal for interaction with MB25. �e presence of a significant 
physical interaction between MB25 and the ZBD should be tested by NMR (see 
section 3.3).  
In contrast, each run with the HBD showed MB25 interacting with the same set of 
residues, of which R452 is the most important one. �e geometry of the site allows 
MB25 to sit comfortably at the bottom formed by I455, L484, L516, and L519 while 
still being able to interact with the R452 guanidinyl group (2-dimensional 
representation of a snapshot from run #4 shown in Figure 3.6). However, it should be 
stressed that these simulation data do not converge upon any single binding mode. 
Indeed, the exact example shown in Figure 3.6 is not maintained for more than several 
tens of ns. �e absence of a single major binding mode in the simulation data may 
simply be a consequence of the system: the combination of a small, flexible protein, a 
weakly binding fragment, and a shallow binding site makes it inherently very dynamic. 
Furthermore, even for more rigid, well-defined binding pockets, fragment binding 
mode prediction is thought to require much longer simulation times of up to 40 µs 
(Linker et al., 2019). �e current results merely suggest the binding site of MB25, not 




Figure 3.6. Example of a binding mode of MB25 to the HBD, observed in simulation run #4. 
Orange dashed line: salt bridge; pink dashed lines: hydrophobic interactions; blue 
background spheres: solvent-accessible surface (scaled). Image prepared using Biovia 
Discovery Studio.  
 
3.3 Verification of simulation results by NMR 
�e simulation results described in the previous section suggest that MB25 prefers to 
bind to the HBD, because all four runs show MB25 associating with the same binding 
pocket and making favourable interactions. To verify this prediction biophysically, the 
two domains were produced with uniform 15N labelling for CSP analysis by NMR.  
For protein characterisation purposes, the ZBD was first produced in rich media 
without added 15N. �e protein was well-behaved throughout the purification. Analysis 
of this material (concentration: 6 mgmL-1) by size-exclusion chromatography 
followed by multi-angle light scattering (SEC-MALS) indicated that it contained 
about 96% monomeric ZBD, with the remaining fraction being a dimer (Figure 3.7). 
Mass spectrometry analysis of the intact, unfolded protein revealed a molecular weight 
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of 11,762.8 Da (expected: 11,762.8 Da). Although the 15N-labelled protein was 
expressed in different growth media, it is assumed that it behaves similarly.  
�e 2D 1H-15N heteronuclear single quantum coherence (HSQC) spectrum of the ZBD 
shows good dispersion of NH resonances (Figure 3.8A), indicating that it is properly 
folded under the experimental conditions. Out of 116 expected NH cross-peaks, 112 
were observed. In the presence of MB25 at ten-fold molar excess, no CSPs are 




Figure 3.7. SEC-MALS spectra of the ZBD (6 mgmL-1) (top) and the HBD (various 





Figure 3.8. (A) 1H-15N HSQC spectrum of uniformly 15N-labelled ZBD at 50 µM. (B) Overlay 
of the spectrum from A (blue) with the spectrum recorded in the presence of MB25 (500 µM) 
(red). The red spectrum was artificially shifted slightly upfield in both dimensions in order to 




Similarly, the HBD was first produced without labelling. SEC-MALS analysis of this 
protein revealed a single population with an estimated molecular weight consistent 
with a monomer. Because the SEC peak retention time was slightly earlier than 
expected for proteins in this size range, and there have been reports of possible 
dimerisation of this protein (Oakley et al., 2005), further analysis was performed over 
a range of protein concentrations. Between 30-600 µM, only the single monomeric 
peak was observed (Figure 3.7). �e unexpected retention time, as well as the 
estimated hydrodynamic radius of 2.2 nm, is likely a result of the non-globular, 
elongated shape of the protein. �e molecular weight of the protein was 17,053.7 Da 
(expected: 17,054.3 Da) as determined by mass spectrometry. �e measured 
molecular weight of the 15N-labelled HBD was 17,258.1 Da, consistent with 97% 
labelling efficiency assuming the protein was not chemically modified.  
�e 2D 1H-15N HSQC spectrum of the HBD shows good dispersion of NH resonances 
(Figure 3.9A), indicating that it is properly folded under the experimental conditions. 
Out of 177 expected NH cross-peaks, 155 were observed. In the presence of MB25 at 
ten-fold molar excess, significant CSPs of a small number of cross-peaks are observed 
(Figure 3.9B). �e observed CSPs did not occur upon addition of either dimethyl 
sulfoxide (DMSO) or acetic acid instead of MB25. Upon addition of acetic acid to 
hundred-fold molar excess, a small number of cross-peaks shifted, only two of which 
also shift with MB25. Together, these results indicate that MB25 is binding to the 





Figure 3.9. (A) 1H-15N HSQC spectrum of uniformly 15N-labelled HBD at 50 µM. (B) Overlay 
of the spectrum from A (blue) with the spectrum recorded in the presence of MB25 (500 µM) 
(red). The inset shows an enlarged example of a region containing cross-peaks with 




To determine whether the shifting peaks belong to residues that could form a binding 
site together, peak assignments are necessary. �e 1H-15N peak assignments belonging 
to the published structure of the HBD (Su et al., 2006) do not match the peaks observed 
here, likely due to differences in buffer pH (pH 6.1 vs. 7.5) or composition. 
Assignments for 134 backbone amides at pH 7.4 were previously determined (Naue 
et al., 2013) and generously provided by Dr. P. Schmieder. �ese assignments closely 
matched, although two cross-peaks could not be observed. Furthermore, based on the 
shared data, asparagine side chain amide NH peak pairs could also be assigned, and 
these assignments also closely matched the peaks observed here. Several peaks could 
not be unambiguously assigned because of partial or complete overlap with cross-
peaks of other residues. Some cross-peak pairs that are overlapped in the apo spectrum 
show perturbation of one of the peaks after addition of MB25. To reveal the identity 
of the perturbed residue, the two overlapping peaks must be distinguished by some 
other feature in which they differ. �e shared data indicated that most of these residues 
have non-overlapping resonances of the carbonyl carbon atoms belonging to the 
backbone amide (formally the carbonyl carbon of the preceding residue, i-1). Since 
these spin systems are chemically connected, a 3-dimensional experiment would be 
able to link the backbone amide H, N, and C atom resonances. �us, even if the H and 
N frequencies of two different residues are identical, they can be distinguished by 
differing i-1 CO resonances. �erefore, the CSP experiment with MB25 was repeated 
and HNCO spectra (that correlate the resonances of these three nuclei) were recorded 
to identify the perturbed residue out of each pair displaying overlapping 1H-15N cross-





Figure 3.10. Comparison of 1H-15N HMQC (top) and 1H-15N-13C HNCO (bottom) spectral 
regions of the R452 backbone peak. Overlay of three spectra of each experiment, containing 
MB25 at 0 (blue), 0.5 (red), or 2 mM (green). The HNCO spectrum is shown at 118.5-
119.0 ppm in the 15N dimension, therefore only R452 and K580 peaks are visible. While 
resonances of these two residues completely overlap in the H and N dimensions at 0 mM, they 
are separated in the C dimension, allowing assignment of the perturbed peak by comparison 
with the previously obtained resonance assignments.  
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Combining the matching assignments with the CSP analysis clearly shows that MB25 
is binding to the site predicted by MD simulations (Table 3-3, Figure 3.11). Out of the 
top ten furthest shifting peaks, seven belong to residues that were present in MD 
simulations proximity analysis top ten (Table 3-1). Two of these residues, R452 and 
N512, were also identified as possible H bond donors to MB25 (Table 3-2). �e two 
residues that are also perturbed by addition of acetic acid, D524 and R559, are the only 
two residues that are not part of the predicted binding site.  
Table 3-3. Top 10 compound-induced CSPs of the HBD.  
MB25 (0.5 mM) AcOH (5.0 mM) 
NH CSP (ppm) σ NH CSP (ppm) σ 
G481 0.089 9.0 H541 0.030 3.1 
L482 0.046 4.6 N540 0.021 2.1 
I455 0.034 3.4 D524 0.016 1.6 
D524 0.031 3.2 T560 0.014 1.4 
R452 0.030 3.0 R559 0.014 1.4 
M451 0.023 2.3 E505 0.014 1.4 
N512 NHδ21 0.022 2.2 Q460 0.014 1.4 
N512 NHδ22 0.022 2.2 N540 NHδ21 0.012 1.2 
R559 0.020 2.0 N540 NHδ22 0.012 1.2 







Figure 3.11. MB25-induced CSPs of assigned HBD NH peaks. Solid line indicates the mean Δδ, dashed line indicates 1σ above the mean. The G481 NH CSP 




�e data presented in this chapter provide a rare example of the correct prediction of 
a fragment hit binding site by unbiased MD simulations. Fragment MB25 was 
previously identified as a hit in a screen for inhibitors of the replisome, and primase 
was indicated as the most likely target based on functional and biophysical data. MD 
simulations were used to quickly assess which primase domain would be most likely 
to bind MB25 and thus should be the focus of future experiments. Few meaningful 
interactions were observed during simulations of MB25 with the ZBD, and indeed no 
interaction whatsoever is observed by NMR. In contrast, NMR experiments showed 
that MB25 perturbs the backbone amide cross-peaks of several HBD residues. �e 
ensemble of perturbed residues forms a binding site on the N-terminal globular part of 
the HBD. �e NMR data are consistent with a binding mode such as is seen in a 
snapshot of simulation #4 (Figure 3.6). �e main features of MB25, its partially 
aliphatic character and the negative charge of its carboxylate, are likely to contribute 
to its affinity for the HBD.  
�e identified binding site is also a binding site for the SSB disordered C-terminal 
peptide (sequence: DDDIPF) (Naue et al., 2013). Both this peptide and its HBD 
binding site are conserved between bacterial species. Strikingly, MB25 has both its 
hydrophobic and charged characteristics in common with this peptide. Indeed, a 
crystal structure of the E. coli HBD shows a crystallographically related C-terminal 
DDIPF sequence interacting with the R452 side chain and the hydrophobic pocket 
(unpublished; PDB: 6cbr). It is likely that the identified binding site has functional 
significance, because SSB is essential for replisome activity. However, the exact roles 
of the SSB C-terminal peptide within the replisome are not known. One of its functions 
is to serve as an anchor point for the clamp loader complex at newly synthesised 
lagging strand primers (Marceau et al., 2011). Here it cannot be ruled out that the 
inhibitory effect of MB25 on the replisome could be because of blocking of the SSB-
clamp loader interaction (since the clamp loader binding site must have similar 
features as the primase HBD), and binding to the HBD would have no functional 
consequence. Primase would then stay bound to the primer-DNA duplex, decreasing 
the effective primase concentration at the replication fork (Yuzhakov et al., 1999). 
�is would then lead to the decreased rate of primer synthesis required to explain the 
observed MB25-induced increase in lagging strand size (chapter 2). However, a direct 
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inhibitory effect of binding to the conserved HBD binding site is more likely. It is 
possible that the SSB C-terminal peptide plays a role in primase-helicase dissociation 
(this has not previously been investigated by others but is tested in section 4.4.3). In 
this case, there are two possible mechanisms of replisome inhibition. �e first is that 
MB25 also induces primase-helicase dissociation, but in an uncontrolled manner (e.g. 
before a primer is fully synthesised). �e second is that MB25 inhibits this SSB-
induced primase-helicase dissociation, causing primase to stay bound to the 
replication fork with a non-functional, primer-DNA duplex-bound RPD. Since SSB 
has multiple functions within the replisome and mutating SSB will affect all of them, 
MB25 might offer an easier way of probing specific aspects of the complex interplay 





4 Elaboration of primase fragment hits using NMR 
spectroscopy and X-ray crystallography 
Preface 
�e author of this manuscript gratefully acknowledges the contributions of James A. 
Brannigan to the work presented in chapter 4, i.e. the expression and purification of 
full-length primase for NMR screening and confirmation experiments, and of primase 
RPD for NMR confirmation experiments and for crystallography; and the initial 
crystallisation and structure refinement of apo RPD. �e author also gratefully 
acknowledges the contributions of Dr. John F. Darby to the work presented in chapter 
4, i.e. the preparation and data collection of the full-length primase NMR fragment 
screen.  
4.1 Introduction 
�e previous chapters described the identification and biochemical characterisation of 
fragment inhibitors of the replisome, and the identification of the primase helicase-
binding domain (HBD) as the binding site of one of these inhibitors. �e half-
maximum inhibitory concentration (IC50) of this hit (MB25) for inhibiting the whole 
replisome is approximately 1.5 mM, which is quite weak. �is chapter will describe 
attempts to evolve this and other fragment hits into more potent probes of primase 
function within the replisome.  
A functional primary screen such as the one introduced in chapter 2 would not have 
identified fragments that bind to replisome proteins without inhibiting their functions. 
As discussed in chapter 1, fragments that bind to a target do not necessarily modulate 
its function. Knowledge of such fragments is nevertheless valuable during structure-
based elaboration of initial hits, because they may reveal new pockets or binding 
modes that can be combined with others to increase potency. To detect such fragments, 
measurement of a biophysical binding event is necessary. Here, NMR spectroscopy is 
used to find fragments from our screening library that bind to primase, and to guide a 
small campaign to understand structure-activity relationships (SAR) that can be used 
to develop high-affinity probes.  
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4.2 Evaluation of fragments by NMR 
4.2.1 Fragment screening against primase by ligand-observed NMR 
Out of the initial set of twenty-five replisome fragment hits, described in chapter 2, 
two compounds were already tested against primase by ligand-observed NMR (LO-
NMR) to confirm that biochemical and biophysical data agreed with each other (Figure 
2.10 and Figure 2.11). One hit seemed to bind to the HBD and one to the RNA 
polymerase domain (RPD). However, it would be desirable to have a larger hit set for 
each binding site to guide SAR investigations. �erefore, our fragment library was 
screened against full-length primase by LO-NMR. �ree experiments were run with 
each sample for higher confidence: saturation transfer difference (STD), water ligand 
observed via gradient spectroscopy (WaterLOGSY), and Carr-Purcell-Meiboom-Gills 
sequence (CPMG) (see introduction section 1.1.2). Since the initial fragment library 
was already old when it was screened against the whole replisome in 2016 (see section 
2.2.1), a subset of refreshed compound stocks was used for this screen, a total of 558 
fragments.  
Compounds were screened at 0.5 mM final concentrations in cocktails of six, against 
full-length wild-type primase at 15 µM. A compound was marked as a hit when its 
spectra showed clear signs of binding in all three experiments. �e CPMG experiment 
was found to be not as sensitive as the other two, often showing spectra with only 
small decreases in compound peak areas when STD and WaterLOGSY showed clear 
signs of binding for the same compounds. �erefore, individual spectra were marked 
with scores of 0, 0.5, or 1, where 0.5 indicates a ‘dubious’ or hard-to-interpret signal. 
A hit was defined as any compound scoring 2.5 or 3 out of three experiments, allowing 
one such spectrum with an unclear result. With these criteria, 59 initial hits were found, 
a 10% hit rate. For fragment screens a 10% hit rate is relatively high but not uncommon 
(Chen & Hubbard, 2009), especially against enzymes with well-defined pockets. Full-
length (FL) primase consists of two protein-macromolecule interaction domains and 
one enzymatic domain that contains a shallow active site, which make a 10% hit rate 
slightly higher than expected.  
4.2.2 Confirmation of fragment hits 
Hits were confirmed by testing them in the presence of FL primase as single 
compounds instead of in their cocktails. Furthermore, they were tested against primase 
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RPD to get a first indication of which domain contained their binding site. At the time 
of screening, the primase zinc-binding domain (ZBD) and HBD were not available in 
sufficient amounts to enable confirmation experiments against them. A selection of 
hits was later tested against the HBD (see section 4.4.2.2). Out of 59 initial hits, 35 
(6%) could be reconfirmed to bind to full-length primase with slightly relaxed criteria 
(score of 2 or higher). Out of these 35 confirmed hits, 24 showed binding to full-length 
primase as well as its RPD. With strict criteria (score of 2.5 or higher), 19 out of 59 
were reconfirmed to bind to full-length primase, 14 of which also showed good 
binding to primase RPD. Figure 4.1 shows example confirmation spectra of two hits 
in the presence of primase RPD: MB106 binds to primase RPD and MB129 does not. 
�e STD experiments (top, purple) show clear peaks above the noise for all but one 
resonance of MB106, while only the methyl group of MB129 shows an STD difference 
peak. �e CPMG experiments (bottom; blue: reference, red: filtered) show at least 
50% signal reduction for all MB106 peaks, but not for all MB129 peaks. �e 
WaterLOGSY experiments (middle, green) show negative peaks for both compounds, 
indicating no binding. However, the relative intensities of MB106 peaks (compared to 
the WaterLOGSY dimethylsulfoxide peak and the 1D compound peaks) are much 
lower than expected, indicating that they are the result of a balance between positive 
and negative signals. �is means that, during signal acquisition, the sample contained 
a population of compound molecules that did not bind to the protein. �is can be 
explained by 1) slow binding kinetics, 2) weak binding, or 3) too short a mixing time 
delay before acquisition. In the case of this fragment screen, explanation 2) is the most 
likely, because fragments rarely display slow binding or high affinity, and because the 
mixing time was set to the same default value (1.5 s) for all screening samples. Since 
the primary goal of this screen was not to identify high-affinity fragments, but to find 
new diverse hits to support development of SAR, such weak binders were evaluated 
as bona fide hits.  
For some of these confirmed hits there were concerns about their aqueous solubility 
based on their predicted partition coefficients (calculated using the AlogP method 
(Ghose et al., 1998)) or on observations during sample preparation. Compounds near 
their maximum solubility sometimes form micelles or soluble aggregates, which could 
appear as false-positives in LO-NMR because they behave as large particles. To test 
for such false-positives, the same screening experiments are run in the absence of 
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protein, and any signs of ‘binding’ must be artefacts. Additionally, 1H spectra of 
compound at single and double concentrations can be recorded to compare peak areas. 
Out of 19 confirmed hits, 4 compounds failed at least one of these tests and were 




Figure 4.1. 1H NMR spectra of two fragment hits (0.5 mM) in the presence of primase RPD 
(15 µM). For each sample three experiments are shown: STD difference (top, purple), 
WaterLOGSY (middle, green), and CPMG (bottom; reference: blue, filtered: red). MB106 









Table 4-1 summarises the final screening results after confirmation. Structures of all 
NMR screening hits against primase can be found in Appendix B. Interestingly, 
neither MB25 nor MB99 (see section 2.2.3) were identified as primase binders. 
Nevertheless, MB25 (in its screening cocktail) received a score of 2 and showed clear 
signs of binding in STD and WaterLOGSY experiments, and MB99 (in its screening 
cocktail) received a score of 1.5 and showed signs of binding in the WaterLOGSY 
experiment and reduction of some but not all of its peaks in the CPMG experiment. 
Furthermore, they were previously confirmed to bind to primase as single compounds. 
When also recalling that these compounds showed inhibition of replisome activity, a 
low but non-zero score in a binding screen does not disqualify these compounds from 
being good starting points for optimisation of primase inhibitors.  
�e 31 hit compounds that were confirmed as true-positive hits show a large diversity 
of chemical scaffolds. Two scaffolds are enriched: 3-phenylpyrazole (MB555, 
MB636, MB911; 3 hits out of 3) and quinoline (MB163, MB500, MB543; 3 hits out 
of 5). However, it is unlikely that hits in either of these sets target the same binding 
sites, because each set contains hits that bind to primase RPD as well as hits that do 
not. Finally, although MB25 was not picked up as a hit in this screen, the other two 
fragments containing the tetrahydrobenzo[c]thiophene core (MB50 and MB655) were. 
However, again, these two hits were found to bind to primase RPD in contrast to 
MB25, casting doubts on their usefulness in SAR. Possibly, binding to the HBD site 
predicted in the previous chapter was prevented by the absence of a negative charge 
to pair with the conserved R452. Notably, this NMR screen found no carboxylic acid-
containing hits except MB307 which bound to the RPD.  
In summary, this NMR screen found 31 primase binders, 22 of which target the RPD. 
Five hits were also identified as replisome inhibitors previously. �ere is no indication 
of binding strength, but since few of these NMR hits inhibit the replisome by more 
than 25% (the cut-off criterium during replisome screening), many could be weak 
binders or target non-functional sites. No obvious SAR appears from the current 
results alone, therefore higher resolution information about the binding domain and 




Table 4-1. Confirmed fragment hits from the NMR screen against primase. Highlighted hits 










1 MB15 2 2 57%  
2 MB31 2 2 41%  
3 MB50 3 1.5 33%  
4 MB51 3 3 32% CPMG 
5 MB85 2 2 27%  
6 MB108 2.5 0 24%  
7 MB142 2 0 20%  
8 MB194 2.5 2 17%  
9 MB228 3 2 16% Solubility 
10 MB286 2 1 13%  
11 MB305 2.5 1.5 12%  
12 MB313 2 0 12%  
13 MB343 2 1 11%  
14 MB345 2.5 1.5 11%  
15 MB361 2.5 0.5 10%  
16 MB371 3 1.5 10%  
17 MB387 2.5 1.5 9%  
18 MB389 3 0.5 9% WaterLOGSY 
19 MB418 2.5 0.5 8% CPMG 
20 MB458 3 2 7%  
21 MB470 1.5 1.5 7%  
22 MB479 3 2 6%  
23 MB497 2 0 6%  
24 MB522 2 2 5%  
25 MB534 3 2 5%  
26 MB615 2 1 2%  
27 MB634 2 1.5 1%  
28 MB660 2 1 0%  
29 MB662 1.5 1 0%  
30 MB666 2.5 1.5 0%  
31 MB715 2 0.5 0%  
32 MB850 3 1 0%  
33 MB870 3 2 0%  
34 MB890 2 0.5 0%  
35 MB980 3 1.5 0%  
 
4.3 Evaluation of primase fragment hits using X-ray crystallography 
FL primase consists of three flexibly linked domains (see sections 1.2.3.3 and 3.1) and 
is not amenable to crystallisation (Zhou et al., 2017). Fortunately, the target domains 
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of many of our fragment hits have been determined, allowing crystallography efforts 
to focus on those isolated primase domains rather than full-length primase. To develop 
these hits into more potent probes, high resolution information about their binding 
modes and protein interactions is needed. �erefore, attempts were made to determine 
their crystal structures in complex with their target domain.  
4.3.1 Crystal structures of RNA polymerase domain in complex with nucleotide 
analogues 
Initial protein crystallisation conditions were identified from a commercial screen, and 
these were optimised towards the published crystallisation conditions (PDB: 1dde 
(Keck et al., 2000)) around pH 5. �e first crystals of the RPD construct comprising 
amino acids (aa) 111-433 (Figure 4.2A) diffracted to 1.5 Å and were resistant to at 
least 10% dimethylsulfoxide (DMSO). �e crystals are tightly packed in the P212121 
space group. Another screening condition, at pH 9, yielded a single crystal in the I222 
space group after seeding. In this crystal the solvent content is higher, making this 
form more attractive for soaking experiments. However, subsequent attempts to 
reproduce the I222 crystal form yielded only the former P212121 crystal form again, 
albeit with a different morphology (Figure 4.2B). A slightly different RPD construct 
comprising aa 111-429 also crystallised under the same conditions, but only in the 
form of needles (Figure 4.2C) with weak diffraction.  
 
Figure 4.2. Different crystals of the RPD construct in the P212121 space group. A) Thin plates 
grew initially at pH 5 and pH 8.5-9. B) Optimisation of conditions and seeding led to crystals 
in the same space group but different morphology. C) RPD construct 111-429 grew into 
needles under the same conditions as in B. 
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�e structures of the primase RPD (aa 111-433) grown at pH 8.5 in the absence or 
presence of DMSO (10%) were solved by molecular replacement and refined at 1.5 Å. 
�ere were no major differences between our structure and published structures (Cα 
root-mean-square deviation: 0.55 Å). Partial density for a DMSO molecule was 
present in a small pocket above the active site. All subsequent, soaked crystals were 
isomorphous, enabling an efficient workflow directly producing difference density 
maps using these initial apo or DMSO-soaked coordinates. A small number of 
compounds caused crystals to crack or dissolve upon soaking. In some cases, after 
data collection unit cell dimensions appeared to have changed significantly, and 
structures had to be solved by molecular replacement.  
Repeated soaking experiments with ATP, adenosine α,β-methyleno-triphosphate 
(ApCpp or AMPCPP), guanosine β,γ-imido-triphosphate (GppNHp or GMPPNP), and 
guanosine 3ʹ,5ʹ-bispyrophosphate (ppGpp), did not yield interpretable difference 
density for these compounds. However, several datasets showed strong density in the 
template-binding groove adjacent to the active site, consistent with a di- or 
triphosphate moiety (Figure 4.3). Possibly, some material contained small amounts of 
hydrolysed phosphates, or these nucleotides were hydrolysed during soaking. 
Alternatively, since the RPD has no sequence specificity and binds oligonucleotides 
weakly, the bases do not interact with the protein and do not adopt specific 
conformations without a complementary template present. Others have noted the same 
with E. coli primase RPD (Corn et al., 2008) as well as other bacterial homologues 
(Rymer et al., 2012; Hou et al., 2018). Although these crystals could be packed in a 
way that occludes the incoming nucleotide subsite, the observation of phosphate 
density in the template binding site shows that most of the active site space is 





Figure 4.3. Positive difference density (green mesh, contoured at σ=3) in the active site groove 
of primase RPD crystals soaked with GppNHp, consistent with the presence of a triphosphate 
moiety. The sugar and base are not observed and are here modelled to extend into the solvent. 
E265, D345, and D347 are catalytic residues. Dashed yellow lines represent intermolecular 
polar contacts.  
4.3.2 Crystal structures of RNA polymerase domain in complex with fragments 
Since soaking with nucleotides showed that the crystallised RPD active site is 
accessible to small molecules, several NMR fragment hits were chosen for soaking 
experiments. Of fragment hits MB15 through MB715 (as presented in Table 4-1), most 
compounds binding the RPD (16 in total) were used for at least two soaking 
experiments. Datasets were obtained for at least one crystal soaked with each fragment 
hit, although dataset quality varied because some compounds caused crystals to crack 
or dissolve. High resolution limits used for refinements varied between 1.4-2.5 Å. 
Unfortunately, no clear difference densities large enough to accommodate ligands 
were found, except in one case. For a selection of compounds prioritised based on their 
inhibitory activity, solubility, and availability of analogues (compounds MB15, 
MB31, MB85, MB615), different soaking concentrations and durations were tested, 
as well as co-crystallisation instead of soaking, but to no avail. Crystals soaked with 
MB666 did show density consistent with partial occupancy of one MB666 molecule. 
MB666 binds to a shallow pocket beneath the template-binding groove, its 
hydrophobic character possibly accommodated by Y142 and L223, and its aniline 
interacting with Q141 and the backbone carbonyl of S138 (Figure 4.4). It is difficult 
to imagine this site being functionally important to the RPD, although it is possible 
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that this surface patch is occupied by DNA template during primer synthesis initiation 
or elongation. Interestingly, although MB666 does not inhibit the replisome, its 
tetrahydrodibenzofuran ring structure is analogous to that of replisome hit MB16, a 
tetrahydrocarbazole. Unfortunately, soaking experiments with MB16 did not result in 
interpretable density for this compound, suggesting that the similarity between MB666 




Figure 4.4. Crystal structure of the RPD in complex with MB666. Difference density (green 
mesh, contoured at σ=2.5) is consistent with the partial presence of a molecule the size of 
MB666. In the binding mode modelled here, the aniline nitrogen makes polar contacts with 
Q141 and the backbone carbonyl of S138. For reference are shown R221 which is part of the 
basic template-binding groove, and catalytic residues E265, D345, and D347. Dashed yellow 
lines represent intermolecular polar contacts. 
�e soaking experiments also included MB25, although this compound was not an 
NMR hit and was shown not to bind the RPD. Nevertheless, crystals soaked with 
MB25 (30-40 mM) overnight showed strong positive difference density consistent 
with the presence of a molecule of MB25 in the same spot where MB666 binds (Figure 
4.5A). MB25 makes an ionic interaction with R221, and its rings lie in almost the same 





hydrophobic pocket on the other side of the α-helix containing Q141 (Figure 4.5B). 
�is pocket, too, is likely of no functional relevance.  
 
  
Figure 4.5. Crystal structure of the RPD in complex with MB25. Difference density (green 
mesh, contoured at σ=3) is consistent with the presence of two molecules of MB25. A) One 
molecule binds in the same spot as MB666, making polar contacts with R221. B) Another copy 
of MB25 binds on the opposite side of the α-helix, making polar interactions with Q132 and 
possibly H150. For reference are shown catalytic residues E265, D345, and D347. Dashed 
yellow lines represent intermolecular polar contacts. 
Since MB25 did not show any signs of binding to the primase RPD during NMR 
experiments, the observation of the RPD-MB25 complex from crystallography is 
likely a result of the soaking conditions. �e crystallography samples, compared to 
NMR samples, contained 30 mM of MB25 instead of 0.5 mM, 15% DMSO instead of 
0.3%, and 34% ethylene glycol species instead of 0%. Further noting that protein 
structure is constrained by packing in a crystal, it appears that NMR experimental 
conditions are much closer to those of the functional assays. �erefore, even though 
MB25 seems to bind to the RPD in crystallo, this must be much weaker binding than 
to the HBD, and probably does not modulate primase function under normal assay 
conditions.  
�e FBLD approach does not require functionally active starting compounds for 
optimisation. Even if MB666 and MB25 do not inhibit primase in their observed 






increased affinity. �e two partially overlapping fragment binding modes present a 
good opportunity for fragment merging (Figure 4.6), where the ideally merged 
compound would interact with both R221 and Q141, resulting in increased affinity.  
 
 
Figure 4.6. Overlay of the binding modes of MB25 (magenta, light grey) and MB666 (cyan, 
dark grey). MB25 interacts with R221 while its rings lie in the same plane as those of MB666 
of which the primary amine interacts with Q141. The R221 guanidinium group is pushed 
slightly away from the cyclohexyl group in the RPD-MB666 crystal structure.  
�is idea of merging was tested by purchasing various analogues (as medicinal 
chemistry support was not available) and testing them by crystallography. Purchased 
analogues fulfilled the following criteria: 1) a negatively charged (at pH 7.5) H bond 
acceptor, approximately opposite 2) a H bond donor, separated by 4 or 5 bonds through 
an aromatic ring. Five such compounds were found available for purchasing and were 
soaked into RPD crystals (Figure 4.7). At initial soaking concentrations (20-30 mM), 
RPD crystals were quickly dissolved by the two tetrazole analogues BL3 and BL5. 
�is problem could be overcome for BL3 by lowering its concentration to 5-10 mM, 
but for BL5 soaking turned out to be impossible. Furthermore, crystals soaked with 
BL4 did not diffract. After data processing, only maps from crystals soaked with BL3 
showed positive difference density in the spot where MB25 and MB666 bind. �e 
density is weak, but matches the two rings of BL3, suggesting partial occupancy 
(Figure 4.8). It is not possible to deduce the orientation of the BL3 amine and whether 
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it interacts with Q141. However, even when modelled in the most favourable 





















Figure 4.7. Structures of initial fragment hits MB25 and MB666, and of four analogues 
attempting to merge their functional groups based on their crystal structures. Only BL3 was 
observed after soaking.  
 
Figure 4.8. Crystal structure of the RPD in complex with BL3. Difference density (green mesh, 
contoured at σ=2.3) is consistent with the partial presence of a molecule the size of BL3. In 
the binding mode modelled here, the tetrazole interacts with R221 but the aniline nitrogen 
does not make polar contacts with Q141. For reference is shown catalytic residue D347. 
Dashed yellow lines represent intermolecular polar contacts.  
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At this point, no options to progress any of the tested hits or analogues by 
crystallography were available. It was suspected that none of these compounds bound 
to the RPD active site. Moreover, the site to which MB25, MB666, and BL3 seemed 
to bind was suspected to be artefactual. Indeed, in crystallo this site is part of an 
artificial small molecule pocket, formed with another protein copy, and forms the end 
of a solvent channel. Modelled fragments were almost as close to one protein molecule 
as to the other, although they did not seem to interact directly with the other (e.g. 
Figure 4.9). Shape complementarity could contribute to fragments binding in this spot. 
�e fact that the RPD active site and substrate-binding groove are open and accessible 
directly next to this spot (as evidenced by the observation of density consistent with 
phosphates, Figure 4.3) suggests that none of the tested fragments preferred the active 
site over this crystallographic pocket. Finally, the fact that MB25 was found in this 
pocket while it did not show binding to the RPD in NMR experiments suggests that 
this pocket may simply attract any small molecule that fits, because of the presence of 
the crystallographically related RPD molecule. �ese doubts, together with the 
absence of high-resolution structural information on the binding modes of other 
fragment hits, were enough to halt SAR investigations with the RPD by 








Figure 4.9. Electrostatic surface view of the RPD crystal soaked with MB25 (see Figure 4.5). 
The next crystallographically related RPD molecule (labelled chain B, dark grey) is very close 
to MB25. Dashed yellow lines represent intermolecular polar contacts.  
4.4 Evaluation of primase fragment hits using NMR 
Since the RPD fragments data were not tractable, the HBD was investigated next. 
Chapter 3 already described that the HBD most likely contains the binding site for 
MB25, and the putative mechanism of inhibition at this site is consistent with 
observations from functional assays. Furthermore, several hits from the NMR 
fragment screen were shown to bind to full-length primase but not the RPD, meaning 
they could inform SAR investigations for MB25 if they bind to the HBD.  
4.4.1 Production of the helicase-binding domain 
�e HBD by itself would be toxic to cells, since it would compete with full-length 
primase in the replisome. �erefore, production of E. coli HBD constructs by standard 
over-expression in E. coli cells would have very low yields. �is concern originally 
contributed to the focus on the RPD as a target (see sections 4.2 and 4.3) and on 
molecular dynamics (MD) simulations instead of physical experiments (chapter 3). 
However, since the simulations showed that the HBD is the target of MB25, and since 
the RPD fragment hits are not tractable, the HBD is an interesting target to pursue. We 
found that growth of BL21(DE3) cells transformed with a pET-based vector carrying 
the HBD gene was indeed very slow (doubling times of approx. 2 hours), suggesting 
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that low levels of ‘leaky’ expression of HBD was inhibiting replication. Growth 
improved when steps were taken to prevent such leaky expression: using cells 
containing the LysS plasmid to prevent T7 polymerase activity, and the addition of 
glucose to the growth medium to repress the lac operon. To improve HBD yields, 
expression was induced at higher cell density than usual (OD600 >1.5). With these 
steps, average yields (after purification) improved from approx. 1 mg per litre of cell 
culture to 5 mg, which was high enough to enable an efficient workflow.  
4.4.1.1 Helicase-binding domain crystallisation 
�e published crystal structure of the E. coli primase HBD (PDB: 1t3w (Oakley et al., 
2005)) shows a domain-swapped dimer where the C-terminal helix hairpins switch 
positions and adopt two different conformations. �ese conformations were shown to 
be different from the solution structure determined by NMR, and likely an artefact of 
crystallisation. �erefore, a new crystal form was sought by starting from broad 
crystallisation screens. Crystals were found in an initial hit condition of sodium 
formate (4 M) but were not reproducible. One of the crystals was tested at the 
synchrotron and diffracted to ~8 Å showing hints of multiple lattices. To optimise 
these crystals, a seed stock was prepared and used to screen other conditions. Needle 
clusters were found in a condition containing sodium acetate (pH 4.6) and ammonium 
chloride (3.5 M). Unfortunately, optimisation screens for these conditions with or 
without seeding did not yield any single crystals. Finally, it was hypothesised that 
addition of the ssDNA-binding protein (SSB) C-terminal peptide (aa sequence 
[MDFDD]DIPF) as a ligand could stabilise the HBD and improve crystallisation, but 
this did not yield any results in the original screens. Because HBD crystals were not 
forthcoming, focus was shifted to protein-observed NMR (PO-NMR) experiments to 
obtain structural information about fragment binding.  
4.4.2 Characterisation of helicase-binding domain fragment hits by NMR 
4.4.2.1 Binding of MB25 to the helicase-binding domain 
�e molecular dynamics (MD) simulations and experimental NMR results presented 
in chapter 3 suggested binding modes of MB25 to the HBD. Most of the 
experimentally determined protein chemical shift perturbations (CSPs) (Table 3-3) 
match with the residues predicted by simulations to be in proximity or contact with 
MB25 (Table 3-2). To further confirm these results, HBD CSPs were measured in the 
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presence of MB25 at 5 mM instead of 0.5 mM, a concentration at which the protein 
should be >50% occupied and which is closer to the simulated MB25 concentration at 
the chosen box volumes (approx. 6.2 mM). Most of the top ten CSPs (Table 3-3) do 
not change between 0.5 mM and 5 mM, except that R559 is replaced by I530, and 
I455 becomes ranked below R452, D524, and M451. To visualise the observed CSPs 
on the HBD structure, relative CSP sizes (i.e. the residue showing the largest shift is 
assigned a value of 100% and all other shifts are set to fractional values relative to 
100%) are shown as a colour spectrum (Figure 4.10A). Compared to the top ten 
residues from MD simulations by proximity or polar contacts (Figure 4.10B), the same 
binding pocket (site 1) is highlighted. However, additional residues that showed large 
CSPs, located on the opposite side of the first α-helix of the HBD, were not predicted 
by simulations.  
�e residues between M521-A531 are part of a flexible loop and the beginning of the 
long helix hairpin, and likely form an interaction surface with helicase (indicated by 
structural and sequence homology to known bacterial primase-helicase structures). 
�e observation that MB25 perturbs the backbone amides of these residues suggests 
either that a second molecule of MB25 binds to this separate site (site 2), or that MB25 
binding to site 1 causes conformational or H bond network changes that extend to this 
loop. If the CSP profile is caused by two separate binding events (the former scenario), 
it is likely that the two binding sites have different affinities for MB25. In that case, 
the two binding events could be distinguished by performing a titration by PO-NMR 
to determine saturation rate constants for each NH cross-peak. To this end, sequential 
1H-15N heteronuclear multiple quantum coherence (HMQC) spectra of 15N-labelled 
HBD were recorded in the presence of MB25 at concentrations between 0.1-5.0 mM. 
CSPs for all peaks were measured and fitted to a one-to-one binding model to estimate 
their binding affinities (KDs). An overlay of spectra for each titration point shows that 
a number of peaks is selectively perturbed by MB25 (Figure 4.11). While calculated 
KD values varied between individual peaks (Table 4-2), all were within the same 





Figure 4.10. Comparison of HBD residues that interact with MB25 (coloured) observed by 
NMR (A) or MD simulations (B). Residues in A are coloured according to CSP magnitude: 
grey for negligible shifts, dark blue for small shifts, through longer wavelengths for larger 
shifts. The largest shift observed was for G481 (red). Note that N512 and W522 sidechain NH 
cross-peaks showed larger shifts than their backbone amides. Shifts in site 2 were not 
predicted by simulations.  
Most peak trajectories were of the same length as the distance between their first and 
last point, suggesting that these shifts are caused by a single event. Notably, there is 
no distinction between fitted values for residues belonging to one or the other site. 
However, shift distances for residues belonging to site 2 were all below one standard 
deviation, except for that of D524. Taken together, these results do not suggest the 
occurrence of two separate binding events of MB25 to site 1 and 2. It is possible that 
the shifts of residues in site 2 are caused allosterically. Since site 2 is most likely 
involved in helicase binding, this would support a hypothesis that MB25 inhibits the 
101 
 
replisome by binding to site 1 of the primase HBD. �is hypothesis is further supported 
by the fact that binding of the SSB C-terminal peptide (aa sequence MDFDDDIPF), 
its most important interactions being between its carboxylates and K447/R452/K518 
(Naue et al., 2013), shows a much larger number of shifts than could be caused by 
direct interactions, including in site 1. Furthermore, the MB25 HBD dissociation 
constant (2.6 mM) and its replisome IC50 (1.5 mM) are in reasonable agreement. �us, 
MB25 seems to have the same putative mechanism of action as the SSB C-terminal 
peptide. Finally, this hypothesis is also supported by primer synthesis experiments 
with helicase and primase (see section 4.4.3.5).  
 
 
Figure 4.11. Titration of MB25 with 15N-labelled HBD by HMQC (overlay of seven spectra). 
Several peaks are highlighted. One of the shifting peaks (L482) is shown in detail and its shifts 






Table 4-2. CSP measurements and fit parameters for the titration of MB25. The average shift 
distance of all visible peaks was 0.023 ppm with a standard deviation of 0.032 ppm. Only 
CSPs of +1σ or larger were used for calculation of average KD. Only fitted KDs with fit errors 





(ppm) KD (mM) KD error 
G481 0.269 0.262 3.4 0.9 
L482 0.164 0.162 2.1 0.1 
R452 0.147 0.134 1.6 0.2 
D524 0.117 0.116 2.3 0.2 
M451 0.100 0.096 4.0 0.6 
I455 0.074 0.073 7.4 4.0 
N512δ2a 0.084 0.071 2.5 0.4 
N512δ2b 0.082 0.069 2.1 0.4 
I530 0.054 0.053 7.3 2.4 
W522ε 0.049 0.049 1.9 0.4 
T515 0.044 0.041 1.4 0.3 
K581 0.027 0.027 7.4 1.5 
W522 0.031 0.026 1.7 0.3 
 
4.4.2.2 Binding of NMR screening hits to the helicase-binding domain 
All original NMR screening hits (Table 4-1) were also tested by LO-NMR against 
unlabelled HBD for direct confirmation of binding. As expected, most hits did not 
show any signs of binding to the HBD. Although the size of the HBD (17 kDa) is close 
to the lower limit of LO methods, potentially causing some false-negative results, 
several hits showed binding to the HBD in at least two out of three experiments (Table 
4-3). Six fragments showed signs of binding to both RPD and HBD and three 
fragments showed preferential binding to the HBD. �ere appears to be no common 




Table 4-3. NMR screening hits that were found to bind to the HBD. Highlighted hits were 










1 MB15 2 2 2.5 57% 
2 MB50 3 1.5 1.5 33% 
3 MB108 2.5 0 1.5 24% 
4 MB194 2.5 2 1.5 17% 
5 MB305 2.5 1.5 2 12% 
6 MB343 2 1 2 11% 
7 MB345 2.5 1.5 1.5 11% 
8 MB497 2 0 1.5 6% 



































Figure 4.12. Structures of NMR fragment hits that showed signs of binding to the HBD in LO-
NMR experiments. MB343 was further investigated because it showed preferential binding to 
the HBD.  
Of these nine fragment hits, MB343 appeared to be the most interesting compound to 
take forward, because it showed the clearest preferential binding. Unfortunately, 
MB343 was not soluble at concentrations higher than the screening concentration 
(0.5 mM), making KD determination by NMR impossible. �e HMQC spectra of 
MB343 with the HBD showed that MB343 perturbs many of the same amides as 
MB25 does (see Table 4-5). �us, MB343 possibly interacts with R452 by accepting 
a H bond with its sulfonamide group while one or both aromatic rings point towards 
the HBD hydrophobic core residues L482, L519, and others.  
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4.4.3 Binding and activity of HBD fragment hit analogues 
Full medicinal chemistry support was not available for this project, but fortunately 
several MB25 and MB343 analogues were commercially available. To track SAR, 
PO-NMR was used to gain low-resolution information about which residues are 
involved in compound binding, and functional assays were used to assess whether 
changes in binding were coupled to changes in compound activity. �e standard 
whole-replisome replication assay, also used for screening and hit confirmation 
(chapter 2), was used to check activity of compounds against the whole replisome, a 
prerequisite since the primary goal of this project is to find probes for the whole 
replisome. A primer synthesis assay was used to assess primase activity specifically. 
In this assay (Figure 4.13), helicase is present to boost primase activity, which 
improves signal accuracy and assay throughput.  
 
Figure 4.13. Primer synthesis assay used to assess activity of analogues against primase. 
Reaction products were separated by polyacrylamide gel electrophoresis. Different reaction 
profiles are observed in the presence or absence of DnaB helicase (the exact cause of the 
difference is unknown but assumed to be dependent on primase-helicase interaction). 
Detection of reaction products by quantifying pixel intensities is based on incorporation of 
radioactive nucleotides.  
As the DNA template in this assay is short (40 b) and single-stranded, helicase 
enzymatic activity does not play a role in primer synthesis. �e increase in primase 
activity with addition of helicase likely results from the increased affinity of the 
helicase-primase complex for the template. �e appearance of shorter reaction 
products is not easily explained, but similar profiles have been reported by others 
(Johnson et al., 2000; Maciąg et al., 2010). If the synthesis of these short primers 
depends on an interaction between primase and helicase (a reasonable assumption), 
they could be used to deduce the mechanism of action of an inhibitor: if an inhibitor 
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directly inhibits primase activity at the active site, then the amounts of all reaction 
products should decrease equally, whereas if an inhibitor disrupts the primase-helicase 
interaction, then the full-length products should remain less affected. Interestingly, 
addition of the SSB C-terminal peptide (sequence MDFDDDIPF), which binds to the 
HBD globular domain, to this reaction results in effects similar to removal of helicase 
(Figure 4.14). �is result suggests that the SSB C-terminal peptide blocks the primase-
helicase interaction.  
 
 
Figure 4.14. Effect of the SSB C-terminal peptide (sequence MDFDDDIPF) on the primase-
helicases primer synthesis reaction. The peptide binds to the primase HBD and could interrupt 
the primase-helicase interaction. DnaB was present at 160 nM. DnaG was present at 200 nM. 
An N-terminal tryptophan was added to the peptide for quantification purposes.  
 
4.4.3.1 MB25 analogues 
First, the MB25 scaffold was investigated in detail to gain an understanding of the 
importance of its pharmacophore features. Of a more practical concern, it was noted 
that benzo[c]thiophene compounds were less common among commercially available 
fragments than benzo[b]thiophenes, and that benzothiophenes with partially 
hydrogenated benzene rings were less common than fully aromatic ones. �erefore, 
fragments with small variations in each of these properties were tested by NMR and 
the two assays. Most analogues were initially tested for HBD binding by LO-NMR to 
save on 15N-labelled protein, after which the positives were also tested by HMQC at 
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single concentration. �e first set of analogues (Figure 4.15) investigated the sulfur 
position, benzene hydrogenation, and presence of the benzene ring. Binding and 
activity data (Table 4-4) seem to agree that an aromatic benzene and either position of 
the sulfur in the ring are tolerated (BL6, BL7). However, replacing the six-membered 
fused ring by smaller single substituents (BL9, BL10) causes loss of binding and 
activity. Keeping the six-membered ring while making it more hydrophilic (BL11) has 
the same detrimental effect, indicating that a hydrophobic group is necessary in that 
position. Interestingly, the replacement of a carbon by a nitrogen next to the sulfur 
(BL8) causes decreased binding and activity compared to the original hit. �e affinity 
of BL8 for the HBD was determined by HMQC titration up to 5 mM, and an average 
KD of 4.8 mM was extrapolated. �is value is based on only four peaks that showed 
significant shifts (R452, G481, L482, D524). �e addition of a nitrogen makes the ring 
slightly less aromatic and slightly more polar, but it is hard to imagine how this could 
affect binding. �e nitrogen replaces not only a carbon atom but also its hydrogen. It 
is known that aromatic rings containing sulfur can form intermolecular interactions 
with carbonyl oxygens, with bond strengths approaching that of H bonds under ideal 
circumstances (Zhang et al., 2015). Such interactions require a CH next to the sulfur 
and are formed between an oxygen lone pair and a σ hole located approximately along 
the S-C bond. Such an interaction would explain why changing the sulfur position has 
lower impact on HBD binding than the replacement of CH by N: the σ hole moves 
less than one bond length. A candidate for the interacting carbonyl could be that of 































Figure 4.15. First set of MB25 analogues tested for activity and HBD binding (see Table 4-4).  
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Table 4-4. Binding and activity results for fragment analogues. Average binding affinities are 
given for analogues that were titrated by HMQC. Amounts of inhibition determined at 1 mM 










1 WMDFDDDIPF yes yes 89% 72% 
2 MB25 yes 2.6 mM ±0.8 28% 35% 
3 MB343 yes yes 16% N.D. 
4 BL6 yes yes 21% 43% 
5 BL7 yes yes 24% 32% 
6 BL8 N.D. 4.8 mM ±2.6 16% N.D. 
7 BL9 N.D. no 4% N.D. 
8 BL10 N.D. no 0% N.D. 
9 BL11 N.D. no 0% N.D. 
10 BL12 no no 0% N.D. 
11 BL13 no 2.4 mM ±0.6 9% N.D. 
12 BL14 no yes 19% 39% 
13 BL15 yes yes (weak) 26% N.D. 
14 BL16 yes 2.2 mM ±0.8 27% N.D. 
15 BL17 no N.D. N.D. 0% 
16 BL18 no N.D. 6% N.D. 
17 BL19 no N.D. 13% N.D. 
18 BL20 no N.D. 7% N.D. 
19 BL21 yes N.D. 12% 27% 
20 BL22 yes 2.2 mM ±0.3 22% 45% 
21 BL23 N.D. yes 29% N.D. 
22 BL24 N.D. no 0% 0% 
23 BL25 no N.D. 29% 39% 
24 BL26 yes yes 58% N.D. 
25 BL27 yes 1.4 mM ±0.3 92% 29% 
 
Next, several analogues were tested that represented slightly larger variations on 
MB25 (Figure 4.16, Table 4-4) to find ways to improve binding affinity. As expected, 
the presence of a negative charge is necessary for binding as replacing it with a neutral 
H bond acceptor of similar size (BL12) abolishes binding and activity. Repositioning 
the carboxyl group (on a fully aromatic scaffold) (BL13, BL14) is tolerated but does 
not improve binding or activity. Adding a H bond donor next to the sulfur as a 
replacement for the hypothesised S-O bond (BL15) is also tolerated. On the benzene 
side of the scaffold, unfortunately very few analogues were commercially available. 
Addition of a single heavy atom (BL16) does not appear to improve potency. 
However, it is reconfirmed that the polarity of this side of the ligand is important, as 
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addition of an amine seems to abolish binding. �e data for this second set of 
analogues suggests that larger additions to the scaffold are needed to improve potency, 
provided they preserve the hydrophobic-negative character of the ligand. 
Unfortunately, no such larger molecules were commercially available that would also 


















BL15 BL16 BL17  
Figure 4.16. Second set of MB25 analogues tested for activity and HBD binding (see Table 
4-4).  
 
4.4.3.2 MB343 analogues 
Because a way forward with the MB25 scaffold was not clear, SAR for hit MB343 
was investigated first. Availability of MB343 analogues with modifications on the 
phenyl group was low, but several compounds with substituents on the sulfonamide 
were commercially available (Figure 4.17). Since MB343 is not soluble above 1 mM 
in HBD NMR buffer, analogues with lower predicted hydrophobicity were prioritised. 
Unfortunately, analogues BL18, BL19, and BL20 containing charged groups did not 
show binding or inhibition (Table 4-4). BL21, however, showed slight activity in the 
whole-replisome assay. BL22, closely resembling MB343, was the most active 
analogue in this set. From these data, it appears that a hydrophobic character is still 
needed, similar to the MB25 analogues series. It is unclear whether the carboxylate on 
BL22 strengthens binding or simply increases solubility. �e increased solubility 
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allowed titrations of BL22 and an average KD of 2.2 mM was calculated. BL22 
perturbed many of the same peaks as MB25 did, including G481, D524, and N512δ 





































Figure 4.17. First set of MB343 analogues tested for activity and HBD binding (see Table 
4-4).  
R452 was also shifted by BL22 by more than one standard deviation, but its curve 
showed a weaker KD (6.5 mM) than those of the other peaks. Determining the R452 
CSPs is somewhat difficult at low concentrations because its 1H-15N cross-peak is 
normally overlapped with that of K580, but in the case of BL22 it was clear that neither 
of these peaks were perturbed at concentrations up to 0.5 mM. �e simplest 
explanation for this differing KD would be a secondary binding event, but that would 
not explain why all other perturbed residues around R452 show similar, lower KDs. 
Alternatively, the observed shift of R452 at high BL22 concentrations could be due to 
non-specific binding or to a different, weaker, competing binding mode. Indeed, 
although parent fragment MB343 could not be titrated to high concentrations, its 
spectrum at 1 mM also clearly shows that R452 is unperturbed. �is suggests that 
binding of the MB343 scaffold does not induce changes to the local environment of 
the R452 backbone amide. In contrast, all MB25 analogues involve R452 shifts that 
saturate at the same rate as the other shifting amides. �ese data suggest that MB25 
and analogues contain a moiety that can shift the R452 amide peak, most likely the 
carboxylate. Furthermore, binding of BL22 depends on a different set of interactions 
(of similar strength to that of MB25) that does not include an R452-carboxylate 
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interaction. �e SAR data for these two series (MB25 and MB343) raised hopes that 
it would be possible to combine the two scaffolds in an energetically favourable way.  
4.4.3.3 Further analogues 
Although further elaboration of fragments became increasingly specific, a small 
number of compounds that fit with the observed SAR so far were commercially 
available. Firstly, it was determined that the BL22 scaffold was already optimal, as 
analogues that contained an extra methylene (BL23), a saturated ring (BL24), or a 
differently oriented carboxylate (BL25) were not more active (Figure 4.18) (Table 
4-4). �e absence of any signs of binding or activity for BL24 suggests that the 
aromatic analogues possibly benefit from intramolecular π-π stacking to form a single 
hydrophobic part from which the sulfone protrudes, not dissimilar to the MB25 
scaffold. If so, the p-carboxylate group would point in opposite direction and would 
not be able to interact with the R452 side chain, as already hypothesised in the previous 
section. Why BL25 with a m-carboxylate would not show binding to the HBD is less 
clear. Possibly, the LO-NMR experiments were false-negatives (as for BL14) that 
unfortunately led to omission of this compound from further PO-NMR experiments. 
However, judging from its inhibitory activities in the two assays, BL25 would not 
have a significantly higher affinity for the HBD than BL22.  
To combine elements of the two scaffolds MB25 and MB343, analogues BL26 and 
BL27 (Figure 4.18) were selected. BL26 also builds on the BL16/BL17 analogues 
(Figure 4.16), adding a bulkier hydrophobic group where a methyl did not improve 
affinity. Unfortunately, though not unexpectedly, BL26 was insoluble in NMR buffer 
above 0.5 mM (as evidenced by diminishing compound proton peak integrals). 
Several lower concentrations below 0.5 mM were tested, but there was no sign of 





























BL26 BL27  
Figure 4.18. Further MB25/MB343 analogues tested for activity and HBD binding (see Table 
4-4).  
BL27 replaces the phenyl ring with a thiophene, making it the analogue with the most 
characteristics from both fragment hits MB25 and MB343, only lacking the aliphatic 
character of MB25. �e ‘ortho’ carboxylate is a placement that had not been tested 
yet. BL27 was found to be a superior compound to MB25 and MB343, in terms of 
both binding (KD 1.4 mM) and inhibitory activity (see section 4.4.3.5).  
4.4.3.4 Analysis of residue interaction patterns 
�e 2D NMR spectral data collected for these analogues, given the amide peak 
assignments, contain detailed information about which analogues interact with which 
residues. Comparison of these interaction patterns gave several insights into the SAR 
of these analogue series (Table 4-5). Roughly taken, residues between 450-520 belong 
to ‘site 1’ (Figure 4.10) and residues between 521-531 belong to ‘site 2’. �e SSB C-
terminal peptide perturbs almost all backbone amides close to these sites, but not the 
N512 side chain. �e two initial primase hits, MB25 from the functional screen 
(chapter 2) and MB343 from the NMR screen (see section 4.2.1), perturb most of the 
non-hydrophobic, solvent-accessible residues of these two sites but not the 
hydrophobic, α-helical residues I455 and L519. As mentioned earlier, a notable 
difference between the two hits is that MB343 does not perturb R452, suggesting that 
it does not interact with the guanidinium group. Overall, it appears that interaction 
with residues G481, L482, and D524 are prerequisites for binding. �ese residues also 
consistently rank among the highest shift distances, suggesting that these distances 
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could be used to estimate binding strength (although this suggestion should be treated 
with caution as it is not possible to rationally predict shift sizes and directions between 
different compounds). Among the MB25 analogues, BL6 and BL16 perturb the 
highest number of residues, indicating that they benefit from their aliphatic character. 
�is observation could be useful in further optimisation of BL27. Furthermore, the 
N512 side chain, amide opposite R452 in site 1, only shows shifts in the presence of 
BL6, BL16, BL13, and the three MB343 analogues, suggesting that molecular weight 
or physical size could also play a role. Finally, BL26 and BL27 were the only 
analogues that induced CSPs of the hydrophobic core residues I455 and L519. Given 
that both these backbones are part of α-helices, it should follow that when their 
chemical environment is changed, that of other residues in the helix could also be 
changed. Further inspection of neighbouring residues of I455 and L519 revealed that 
their backbone amides are indeed perturbed more than with other analogues, but not 
far enough to become significantly above average. BL27 is the analogue that causes 
the most CSPs and is also the only analogue with noticeably improved affinity and 
activity. �is analogue together with the partially aliphatic MB25 and analogues is 
also able to interact with the N512 sidechain, the only amide that is not perturbed by 
the SSB C-terminal peptide. �erefore, N512 provides a possible way of 




Table 4-5. Comparison of HBD-binding compounds and their induced CSPs. 1H-15N HMQC spectra of the HBD in the presence of compound (0.5-1.0 mM) 
were compared with the presence of only DMSO, and peaks that shifted by more than the average distance are marked as perturbed. N.D.: not determined. KD 
value of SSB Ct was taken from (Naue et al., 2013).  
Fragment Parent hit KD (mM) M451 R452 I455 G481 L482 N512δ T515 L519 W522ε D524 I530 
SSB Ct  0.01 X X X X X  X X X X X 
MB25  2.6 ±0.8 X X  X X X X  X X X 
MB343  N.D.    X X     X X 
BL6 MB25 N.D. X X  X X X X  X X X 
BL7 MB25 N.D.  X  X X  X  X X  
BL8 MB25 4.8 ±2.6 X   X X     X  
BL13 MB25 2.4 ±0.6  X  X X X    X  
BL14 MB25 N.D.  X  X X     X  
BL15 MB25 N.D. X   X X     X  
BL16 MB25 2.2 ±0.8 X X  X X X X  X X X 
BL22 MB343 2.2 ±0.3    X X X X  X X X 
BL23 MB343 N.D.    X X X      
BL26 MB25 N.D. X X X X X X X X  X  






























































4.4.3.5 Functional characterisation of BL27 
BL27 was titrated against the replisome to determine an IC50 of 0.2 mM (Figure 4.19). 
�is value is significantly different from its HBD binding constant (1.4 mM), 
suggesting that BL27 may additionally inhibit another part of the replisome. Since the 
HBD binding site binds the SSB C-terminal peptide, and replisome subunit χ also 
binds this peptide, it is possible that BL27 also binds to the χ peptide-binding site, 
which would inhibit sliding clamp loading. However, BL27 also inhibits the primase-
helicase interaction within the replisome, because it has the same concentration-
dependent effect on lagging strand sizes as MB25 (Figure 2.8).  
 
 
Figure 4.19. Titration of BL27 against the whole replisome. Interpolated sigmoidal curve 
(solid line) and its 95% confidence intervals (dotted lines) are shown.  
Furthermore, while MB25, MB343, and BL22 were too weak to allow accurate IC50 
calculation when titrated against the HBD in the primase-helicase primer synthesis 
assay (Figure 4.13), BL27 showed higher inhibitory activity with an average IC50 of 
1.2 mM (Figure 4.20). Most interestingly, BL27 seems to inhibit synthesis of shorter 
primers (lower band on gel) more effectively, and while these products are reduced to 
almost zero at the highest BL27 concentration, the amount of full-length products 
(upper band) never falls below that observed in the absence of helicase. �is indicates 
that primer synthesis is not directly inhibited at the active site, but rather that BL27 
counteracts the presence of helicase. �e IC50 of BL27 for the lower band products is 
around 1.0 mM, in between the BL27 HBD affinity (1.4 mM) and whole-replisome 
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IC50 (0.2 mM). Taken together, these data indicate that BL27 inhibits the replisome 
by disrupting the primase-helicase interaction, and possibly by a second mechanism 
not involving primase. Further optimalisation of BL27 for the HBD peptide-binding 
site would also increase specificity, making it a promising tool for probing HBD 




Figure 4.20. Titration of BL27 in the primase-helicase primer synthesis assay. An example 
replicate gel showing radioactive products is shown. BL27 concentrations ranged between 
0.025-3.5 mM. In the graph, relative intensity counts for the whole lane, upper band, and 
lower band separately are shown. Interpolated sigmoidal curves (solid lines) and their 95% 
confidence intervals for upper and lower bands (dotted lines) are shown. Best-fit values of the 




�e work presented in this chapter focused on primase as the target of a standard 
biophysical FBLD project, because primase was previously identified as the target of 
a whole-replisome fragment hit. An NMR fragment screen against primase alone 
yielded a reasonable 6% hit rate, with most hits binding to the enzymatic domain of 
primase. Although the primase active site was the obvious target site, crystallographic 
efforts did not reveal any active site binders, possibly due to a crystal packing 
unfavourable for compound soaking. Focus was shifted towards the primase HBD, as 
it had previously been indicated as the domain binding MB25. �e NMR screening hit 
MB343 showed clear preference for the HBD in LO-NMR binding experiments. SAR 
was explored for these two hits, MB25 and MB343. In the absence of reproducible 
crystals, information on fragment binding modes was obtained at the whole-residue 
level by PO-NMR using residue assignments that were previously obtained (see 
section 3.3) (Naue et al., 2013). Two important determinants of binding were 
identified from the first set of MB25 and MB343 analogues: presence of a bulky 
hydrophobic part (with slight preference for aliphatic) and of an adjacent negative 
charge. �e best analogue, combining elements of the two original hits, showed 
improved binding and inhibitory activity against the whole replisome and the primase 
HBD. �ese SAR investigations mark BL27 as a promising HBD ligand for further 








5 Covalent modification of the replisome for target 
identification 
Preface 
�e author of this manuscript gratefully acknowledges the contributions of Dr. James 
D. Firth to results presented in this chapter, i.e. the synthesis of diazirine and other 
derivatives of various replisome fragment inhibitors.  
5.1 Introduction 
Fragment-based lead discovery (FBLD) projects often start with an identified target, 
and there is considerable knowledge and experience with using fragments in 
biophysical and purified-enzymes assays. �e previous chapters described how, after 
screening the whole replisome for inhibitors, the binding site of hit MB25 was 
identified through many different experiments involving functional and binding assays 
and computational simulations. �ese types of experiments give detailed information 
about the system investigated and are most often used for single protein targets. 
However, as described in chapter 1, the replisome is not a single target even though it 
acts as a single system and consisted here of purified components. Some of the 
identified fragment inhibitors did not appear to inhibit any of the tested sub-
components of the replisome. �is chapter describes preliminary research to use 
chemically reactive fragments to identify the target protein or protein complex to 
which fragment hits bind. �is area of research, where complex biological systems are 
probed with molecular precision, often using chemical compounds, is called chemical 
biology.  
Chemical probes are molecules that have been designed to bind to a protein, serving 
as a tool to answer questions about the identity and function of the protein in its native 
environment (Arrowsmith et al., 2015; Gerry & Schreiber, 2018). Detection of probe-
protein complexes is most often done by modifying the probe with groups that enable 
detection or further work-up procedures, e.g. fluorescence microscopy (if the probe 
can be modified with a fluorescent group), mass spectrometry (MS), or affinity 
purification (Schenone et al., 2013). For a long time, the chemical complexity of the 
cell has been seen as requiring high affinity and specificity of effective chemical probes 
(Bunnage et al., 2013). Fragments were expected to meet neither of these criteria, and 
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while it may be possible to optimise fragment affinity, this would be pointless when 
the target list contains hundreds of equally ranked proteins. �ere have been no 
published examples of the use of fragments for whole-cell screening until recent years 
(Parker et al., 2017; Ayotte et al., 2018). In fact, while fragment-protein affinity limits 
are easily derived from the maximum number of favourable interactions that a 
fragment-sized molecule can make, the rules for fragment specificity are less clear. 
�ese recent studies showed that fragments can indeed be specific towards one 
phenotype or one or few protein targets, exerting biological effects by modifying the 
activity of their targets. �e approach by Parker et al. (Parker et al., 2017; Galmozzi 
et al., 2018; Wang et al., 2019) uses small sets of fragments that have been modified 
with photoreactive groups to enable direct target identification by MS-based 
proteomics. Target identification by MS is based on the observation of unique signals 
of protein chains that have been covalently modified by reactive compounds. In case 
of the replisome, such an approach could also be of interest, even in a retrospective 
way, since the current data on most replisome hits did not reveal their targets (see 
section 2.1). �is chapter will present the results of two approaches for MS-based 
detection of covalent replisome inhibitors (Figure 5.1). First, several previous 
replisome hits were modified with a UV-sensitive diazirine group in the hope that they 
would covalently attach to their binding site during the replication reaction upon 
irradiation. Second, a small set of thiol-targeting electrophiles was screened against 
the replisome to find out whether there are native sites within the replisome that can 


















Figure 5.1. Two approaches for covalently modifying proteins with small molecules. The first 
uses the photoreactive diazirine group to generate carbene species which will insert into any 
nearby RʺH bond (most often CH or OH). The second approach uses electrophiles of varying 
strength to react with surface-exposed cysteines. In both approaches the R group confers 
binding site specificity.  
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5.2 Photoreactive replisome hits 
Reactive groups can lead to non-specific labelling of proteins if their reactivity cannot 
be controlled. Diazirine is a chemical group with inducible photoreactivity which can 
provide a clean way of crosslinking with few drawbacks. In case of fragments, the two 
main concerns are the relative size of the diazirine-containing group which could 
significantly alter the affinity or specificity of the whole molecule, and the low original 
affinity of the fragment which leads to low levels of crosslinking. With sufficiently 
high-resolution MS methods, crosslinking levels down to a few per cents can still 
result in good data (Grant et al., 2019). �e influence of the diazirine-containing group 
on fragment binding is not known beforehand. In case of screening this is not of 
serious concern because it is still probable to find at least one hit that is not influenced. 
In the present case of known hits to be modified, however, the influence of the diazirine 
modification on fragment activity should be investigated.  
5.2.1 Design of diazirine derivatives of replisome fragment inhibitors 
Two well-characterised fragment inhibitors, hit MB25 and the literature control 
fragment used during screening (see section 2.1) (Yin et al., 2014) (hereafter F5), were 
chosen to assess the influence of diazirine modification on fragment binding and 
activity. �e target of each fragment was known (primase for MB25, sliding clamp for 
the control fragment), as well as a binding mode allowing the prediction of a position 
where modification with the diazirine group would result in minimal interference 
(Figure 5.2). In case of F5, a published crystal structure of F5 in complex with its 
target (the β2 sliding clamp) (Yin et al., 2014) showed that the two rings are already 
twisted with respect to each other, therefore any of the four meta-positions were good 
candidates for modification. �e ortho-position of the benzoate is most directly 
pointing towards the solvent, but it was feared that modification there could influence 
H bonding by twisting the carboxylate. �erefore, the 2ʹ-position on the p-
fluorophenyl ring (meta relative to the fluoride) was chosen for modification (Figure 
5.2, compound D1). In case of MB25, the optimal attachment position was difficult to 
predict because previous structure-activity relationships experiments (see section 
4.4.3.1) suggested that the thiophene does not have any positions that can be modified 
without impeding binding. Furthermore, multiple binding modes were sampled during 
simulations, which did not reveal any of the aliphatic carbons as being more solvent-
exposed than the others. To increase chances of at least one productive binding mode, 
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the conformationally flexible 6-position was chosen for modification, and a synthetic 
route that would result in a racemic mixture (Figure 5.2, compound D2). �e position 
of the sulfur was changed for greater synthetic accessibility, a change that was 
previously determined to have little impact on compound activity (compare MB25 and 
BL6, Table 4-4).  
 
















Figure 5.2. Proposed modification positions based on binding modes from co-crystal structure 
(F5) (Yin et al., 2014) or simulations (MB25) (see section 3.2). For each original fragment 
F5 and MB25, an example binding mode structure is shown. The binding modes suggest 
possible vectors for modification with the shown diazirine-containing R group which would 
least impede fragment binding. Further discussed in the accompanying text.  
�e modification consisted of a diazirine group flanked by two ethylenes, a terminal 
alkyne that could serve as a handle for labelling for fluorescence or affinity purification 
experiments via click chemistry, and a carboxylic acid for nucleophilic acyl 
substitution by the aminated ligand. �e resulting R-group is identical to the one used 
by Parker et al. (Parker et al., 2017). Two control compounds were also synthesised 
to test the influence of various parts of the diazirine-modified fragments: F5 modified 
with n-hexanamide without diazirine and alkyne groups (D3), and an R group where 
the fragment part is a single methyl group (D4).  
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5.2.2 Testing of diazirine derivatives 
First, the modified fragments and various control compounds were tested for replisome 
inhibition under standard non-crosslinking conditions (absence of sunlight and other 
sources of UV light) in the original whole-replisome assay used throughout this work 
(see section 7.2). It was confirmed that the diazirine-alkyne moiety alone does not 
inhibit replication. Modification of F5 at the 2ʹ-position did not significantly change 
its activity, showing that the choice of this position based on the crystallographically 
determined binding mode was correct. Modification of BL6 also resulted in similar 
inhibition. Although the 6-position of BL6 is not expected to point directly towards 
the solvent, and analogue D2 is a racemate, the observed activity suggests that any 
interactions between primase and the diazirine moiety are neither repulsive nor strong 
enough to significantly change the activity of the whole molecule. An NMR saturation 
transfer difference experiment also showed signs of binding of D2 to the primase 




































Figure 5.3. Fragment inhibitors and their modified analogues tested for replisome inhibition 
under standard non-crosslinking conditions. Compounds were tested at 0.5 mM except for 
BL6 and D2 which were tested at 1 mM. Diazirine derivatives showed similar inhibition to 
their original fragment parents, and the diazirine-alkyne group alone (D4) did not show any 
non-covalent inhibition of the replisome, suggesting that the modification does not change the 
binding and activity of the original fragment parts.  
Next, the influence of UV irradiation on compounds and replisome components 
separately was investigated. At 0.5 mM in phosphate-buffered saline, the three 
diazirine analogues showed different conversion rates under UV irradiation, as 





















needs approximately 30 minutes of irradiation before complete conversion, diazirine 
groups attached to fragments (D1 and D2) seem to be more sensitive. �e presence of 
a non-covalent fragment is sufficient to increase sensitivity (see D4 + F5). Possibly, 
F5 re-emits UV light at wavelengths that are closer to the diazirine absorption 
maximum. �e effect seems limited to F5, as D2 is slower to degrade than D1, and the 
presence of other aromatic molecules such as nucleotides that are present in assay 






Figure 5.4. Conversion of diazirines under UV irradiation measured by NMR. An overlay of 
D4 spectra at time points between 0-30 minutes is shown, with an expanded region where 
ethylene peaks (2.10 ppm) disappear and new peaks (2.25-2.35 ppm) appear with increasing 
UV irradiation time (blue spectrum = 0 min, orange spectrum = 30 min). The chart shows 
fractions of remaining diazirine molecules after each time point relative to initial values at 
time point zero (backgrounds subtracted).  
Irradiation of different assay components causes large decreases in subsequent 
replication activity (Figure 5.5). Not unexpectedly, irradiation of the circular dsDNA 
template almost completely inhibits subsequent replication reactions. Nucleotides and 



























activities. �e most important consequence of these observations is that it would be 
impossible to crosslink diazirines to active replisomes using the current approach, 
because replisomes would stall and disassemble before diazirines can be completely 
converted. Unfortunately, this meant that the diazirine crosslinking approach in this 
form was not suitable for identifying binding sites of hits that did not seem to inhibit 
any replisome subcomponent (e.g. MB7, Figure 2.5), as the expectation for such hits 
was that they might bind to sites that are only formed when the replisome is active. 
One possible solution to this problem would be to use high-power UV beams to 
decrease diazirine-to-carbene conversion times to just several seconds (Horne et al., 
2018). Such equipment was not available during the current project. Alternatively, the 
use of light sources with narrower wavelength profiles could limit damage to the 
replisome or to dsDNA template, although some forms of DNA are known to take 
damage from wavelengths up to 365 nm (Tyrell, 1973), and the exact absorption 
maximum for diazirine groups could be different for each derivative.  
 
Figure 5.5. Effect of UV irradiation on different replication reaction components. Each 
component was irradiated for 5 minutes, then added to reaction mixtures as normal. UV pre-
irradiation of each component severely impairs assay activity.  
Since the targets of the control compounds were known, pre-irradiation of protein and 
diazirine together could indicate whether crosslinking at the inhibitory site occurs. Pre-
incubation and -irradiation of D1 with the β sliding clamp indeed renders the whole 



















inactivated. �e effect cannot be explained by simple inactivation of the sliding clamp 
by UV light directly, because irradiation of D4 and β still permits subsequent 
replication.  
Several attempts were made to directly observe a crosslinked D1 + β product. 
Unfortunately, the available protein quantities were insufficient for MS experiments. 
Attaching an azide derivative of a fluorescent dye to the crosslinked product via click 
reaction (Presolski et al., 2011) showed low levels of fluorescence on polyacrylamide 
gel at the position expected for β (not shown), but also showed similar levels after 
crosslinking between D4 and β or between D1 and primase, suggesting that these 
signals are mainly due to non-specific crosslinking.  
In conclusion, diazirine derivatives of two known fragment inhibitors were used to 
show that this type of crosslinking chemistry can be used without much impact on the 
functionality of the original fragments. Activity assays showed that crosslinking D1 
to its target (β) enhances inhibitory activity, suggesting that D1 was covalently 
attached to the protein-protein interaction pocket of β. However, attempts at direct 
observation of the crosslinked molecule failed. Furthermore, UV irradiation of the 
replisome using standard equipment was found to be unsuitable for in situ crosslinking 
experiments as neither DNA template nor replisome subunits could tolerate irradiation 
for the duration that was found necessary for complete conversion of diazirines. For 
in situ crosslinking of inhibitor diazirine derivatives to active replisomes followed by 
direct observation and identification of crosslinked products by MS, more bespoke 
equipment would be needed as well as higher protein quantities than were used 
previously.  
5.3 Targeting replisome cysteines 
Cysteine thiol groups are often the target of protein covalent modification, as they are 
the most reactive (when solvent-accessible) and are rare enough that most have unique 
molecular environments. �iol-reactive compounds can be developed in two different 
ways: by introducing an electrophilic group to a known non-covalently binding ligand, 
or by screening for reactive electrophiles and subsequently adding or modifying non-
covalent selectivity groups (Hallenbeck et al., 2017; Lonsdale & Ward, 2018; 
Erlanson et al., 2004; Keeley et al., 2020). Instead of exchange rate constants, reaction 
rate constants and specificity determine the largest part of the effectivity of a covalent 
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ligand. In a fragment-based approach to covalent ligands, the specificity element can 
be built up in much the same way as for non-covalent ligands, allowing the separate 
optimisation of covalent bond formation rate and target specificity (Miller et al., 2013; 
Kathman et al., 2014; Kathman & Statsyuk, 2016). Here, the replisome was probed 
for native cysteines that could support covalent inhibition of replication.  
5.3.1 Feasibility of replisome inhibition by thiol-targeting fragments 
�e replisome contains several solvent-accessible cysteines that could be targeted with 
electrophilic fragments. With crystal structures of most replisome subunits publicly 
available, a detailed analysis of replisome cysteines was made using the Cpipe web 
server (Soylu & Marino, 2017). �is pipeline calculates solvent-accessible surface 
areas of cysteines and attempts to make predictions about the functions of reactive 
cysteines. Five cysteines belonging to four replisome proteins were predicted to be at 
least somewhat reactive (Table 5-1). Eight other cysteines were highlighted as well, 
but as these belong to zinc-binding folds they were ignored. A few minor parts of the 
replisome were not present among the analysed structures: the α oligonucleotide-
binding domain containing one cysteine, the primase zinc-binding domain containing 
four cysteines (three of which coordinate zinc), the τ helicase-binding and polymerase-
binding domains containing one cysteine, and the SSB carboxyterminal disordered 





Table 5-1. Cpipe analysis of published replisome subunit structures. SASA: solvent-accessible 









Cys (A2) Note 
helicase 6qem -   No cysteines 
helicase loader 6qem C78 7.5 36.7  
α 2hnh C154 6.6 12.9  
Primase RPD 1dde None    
Primase HBD 6cbr None    
β 1mmi 
C260 6.7 14.8  
C333 4.6 25.6  
ε 1j53 None    
τ 3glf 
C64 6.0 14.7 
Zinc finger 
C73 8.5 43.8 
C76 4.4 17.0 
C79 4.3 10.4 
δ 3glf None    
δʹ 3glf 
C50 3.9 17.1 
Zinc finger 
C59 6.6 37.0 
C62 4.0 16.3 
C65 5.48 11.46 
χ 3sxu None    
ψ 3sxu C85 5.27 13.9  
θ 2ae9 -   No cysteines 
SSB 4mz9 -   No cysteines 
 
Among the five cysteines predicted to be potentially reactive, C78 of the helicase 
loader is the most interesting one because it is located close (approx. 9 Å) to the ATP-
binding site of this enzyme (Arias-Palomo et al., 2019) (Figure 5.6). Two cysteines of 
the sliding clamp are also of interest because both are located on the inside of the 
dsDNA-binding ring, possibly giving the opportunity to sterically hinder clamp 
loading. �e two remaining cysteines predicted to be reactive, one belonging to α and 
one to ψ, are of less interest because they do not appear to be of structural or catalytic 
importance and are less solvent-accessible than the first three cysteines mentioned. 
�ese predictions were sufficiently encouraging to conduct an initial screen of 




Figure 5.6. Structures of the E. coli helicase loader (brown surface) in complex with the 
helicase (blue cartoon) (Arias-Palomo et al., 2019) and of the E. coli sliding clamp homodimer 




To enable screening of thiol-reactive electrophilic fragments, the replication reaction 
conditions needed to be changed to remove any excess reactive thiols. �e replisome 
activity assay that was employed in previous chapters contains large amounts of 
dithiothreitol (DTT) (10 mM) to maintain the replisome in its native reduced state, and 
bovine serum albumin (BSA) (1.5 μM) to promote general stability of dilute proteins 
in vitro. Omission of BSA did not significantly affect replisome activity (not shown). 
Omission of DTT reduced the activity of the replisome by approximately 40% (Figure 
5.7). Replisome subunits were stocked under reducing conditions, which could explain 
the remaining 60% activity. �e combined concentration of DTT from replisome 
subunit stocks in the final reaction mixture is 240 μM, at unknown stages of oxidation. 
As the concentration of fragments during screening was set to 500 μM, these 




Figure 5.7. Effect of varying concentrations of DTT on replisome activity. A strong reducing 
environment appears to be important to replisome activity.  
 
5.3.2 Screening of a small electrophilic library 
A set of 28 electrophilic fragments covering a broad range of electrophilic reactivities 
(Ábrányi-Balogh et al., 2018) was used to find suitable warheads for replication 
inhibition. �e electrophilic groups were attached to the 3,5-bis(trifluoromethyl)-
phenyl scaffold, covered different types of mechanisms (e.g. Michael addition, 





















stable as measured by incubation with glutathione. �e set also contained two non-
reactive control compounds. Structures of all screened electrophiles can be found in 
Appendix B. To increase chances of covalent bond formation, each compound was 
incubated with the inactive replisome at room temperature for 30 minutes before 
starting replication at 37 °C for 13 minutes. �e two non-reactive control compounds 
(ML17B and ML28) were found to weakly inhibit replication, and three electrophiles 
(ML21, ML25, ML30) showed higher inhibition than these control compounds 

















Figure 5.8. Screening results for the electrophilic fragments set against the replisome and 
structures of the top three hits.  
ML25 is one of the most reactive electrophiles, even showing partial degradation in 
aqueous phosphate buffer during NMR analysis, and thus would be expected to show 
up as a hit in most screens. However, another known thiol-reactive fragment, the 
maleimide ML20, did not show increased inhibition over the control compounds. 
ML21 and ML30 have similar structures and mild reactivities. Isothiocyanates in 
natural products are associated with various health effects through covalent protein 
modification mechanisms, but cyanamides are uncommon in bioactive compounds. 
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�e finding that both fragments were hits possibly suggests a specific action on the 
replisome.  
Since ML21 and ML30 were expected to have mild reactivities and slow reaction 
rates, their inhibitory activities were measured after various incubation times prior to 
starting the replication reaction. If these hits acted via a covalent mechanism, their 
activities would be expected to correlate with incubation time. However, a clear 
correlation was not observed (Figure 5.9), except for a slight increase in inhibition 
between 0 and 10 minutes of incubation.  
 
Figure 5.9. Replisome inhibition by electrophilic fragment hits after various incubation times. 
Inhibition does not appear to be time-dependent, suggesting either a fast reaction or a non-
covalent mechanism of inhibition.  
To directly confirm whether ML21 or ML30 covalently bound to one of the cysteines 
of interest (the helicase loader or the sliding clamp), various attempts were made to 
observe the expected covalent reaction products by MS. No mass additions were 
observed for either protein after incubation under conditions similar to those used 
during activity assays. Several parameters were then changed to make reaction 
conditions more favourable and observation of covalent modification more likely, 
although the range of conditions was limited by moderate protein stability and 
solubility. Increased electrophile concentrations (0.5-5.0 mM), increased reaction 
times (1-21 h) and temperatures (22-37 °C), and various buffers (HEPES, Tris, 
phosphate) were tested, but no covalent modifications of the helicase loader or the 
sliding clamp were observed. �ese results suggest that ML21 and ML30 may inhibit 
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replication by a non-covalent mechanism of action, a hypothesis that is supported by 
the fact that these hits are structurally almost identical.  
5.4 Conclusion 
�e experiments described in this chapter failed to produce any covalent protein-
fragment complexes that were observable by MS. In case of the cysteine-targeting 
approach, the most likely explanation is that the replisome does not contain reactive 
cysteines that can transmit activity changes when covalently modified. Alternatively, 
it is possible that one or more cysteines were modified but the phenyl scaffold was not 
able to inhibit replication due to suboptimal structure or size. It would be interesting 
to screen covalent libraries that contain more variety of scaffolds, or to select a known 
binder (such as ATP in case of the helicase loader) and grow it towards the closest 
cysteine. However, these alternative approaches would fall outside the purpose of this 
project to identify replisome-binding fragments and their targets ab initio.  
In case of the photoaffinity approach, several results indicated that this approach could 
be viable in principle. Modification of known fragment binders with a diazirine-
containing group did not interfere with their activity, and the putative crosslinking of 
one fragment to its protein target resulted in increased inhibitory activity. However, 
the effect of UV light on active replisomes prohibited in situ crosslinking. To directly 
crosslink a fragment inhibitor to an unknown target during replication would require 
considerable optimisation of reaction conditions to avoid replisome breakdown. �is 
could be achieved by decreasing diazirine-to-carbene conversion times from several 
minutes to several seconds. Additionally, it would be interesting to test whether there 
are specific wavelengths that can activate diazirines but do not damage dsDNA and 









�is project was based around the first results of a fragment screen for inhibitors of 
the E. coli replisome. �e idea of screening against an ensemble of targets was novel, 
so initially the range of expected possible outcomes included complete inhibition by 
all fragments due to the high concentration of compound used, as well as no effects by 
any fragment due to the size and complexity of the replisome. �e screening results 
were exciting because they appeared to be similar to those of most fragment-based 
campaigns which target single proteins: an initial hit rate of 10% and chemical 
diversity among hits with some structural motifs showing signs of enrichment.  
�e number of hits decreased slightly after compound quality control, notably among 
the hits that were most active. In hindsight, it was surprising to find so many fragments 
that more than halved the activity of the replisome (39 fragments, of which 18 later 
appeared to be DNA intercalators). �is emphasises that more attention should have 
been paid to compound behaviour following the initial screen. �is would have shifted 
attention to the eighty fragments that showed moderate inhibition and additional 
interesting compounds may have been confirmed for further study. However, the 
fragments hits that were confirmed did show a range of activities against different 
components of the replisome (these results could be included in a small publication on 
the in vitro screening of fragments against a large molecular machine) and the work 
in this thesis focused on these. 
For one confirmed hit, MB25, target identification was achieved through a 
combination of functional and biophysical experiments with molecular dynamics 
simulations. �e first hints that MB25 might inhibit primase function came from the 
whole-replisome activity assay itself, as this fragment increased lagging strand sizes. 
NMR binding experiments with primase suggested that MB25 did not bind to the 
active site of primase, which would have been the simplest explanation. Since primase 
is a flexible protein with multiple separate domains, binding mode identification by 
crystallography (standard practice in FBLD) was not straightforward. Instead, an 
attempt to identify the site of action was made by conducting molecular dynamics 
simulations with the two non-enzymatic domains of primase. �ese simulations 
suggested specific binding to a conserved peptide-binding site on the helicase-binding 
domain, and these results were subsequently confirmed by protein NMR.  
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Simulation data also proved useful during hit optimisation because crystallisation of 
the MB25 target domain failed. Protein peak assignments, kindly provided by others 
(Naue et al., 2013), enabled preliminary structure-based hit optimisation at the residue 
level. Structure-activity relationships were monitored by both NMR binding data and 
enzymatic activity data for both DNA replication and RNA primer synthesis. Because 
the accessible chemical space was limited by commercial availability of hit analogues, 
a more ‘traditional’ single-target screen with primase was conducted. �is yielded a 
novel scaffold (MB343) that was shown to interact with the MB25 binding site. 
MB343 itself did not inhibit the replisome, but combination of elements from MB25 
and MB343 yielded a compound with improved binding as well as inhibitory activity. 
�is result shows the benefits of collecting both binding and activity data. Fragments 
may bind at or close to a functionally interesting site on a protein but will not show 
functional effects until the fragment is optimised. Finally, during the hit optimisation 
stage a minor but interesting new piece of information from a biochemistry perspective 
was discovered: that binding to the SSB-binding site of primase also influences 
primase-helicase binding. �e prediction of the MB25 binding site and subsequent 
mechanistic and fragment optimisation experiments could be published as an example 
of successful fragment binding site identification and characterisation in the absence 
of atomic-resolution (crystallographic) data.  
Attempts were made to develop a chemical strategy that could identify the exact target 
of a replisome inhibitor based on recent new ideas in chemical biology. Compounds 
were synthesised that combine a fragment with a chemical warhead that can be 
activated to covalently attach to a protein if the fragment binds, using mass 
spectrometry to identify and characterise the resulting protein-compound conjugate. 
Pilot work demonstrated proof of principle with an isolated protein from the replisome 
and activated compounds derived from fragments that are known to bind to it. 
However, further work is needed to adapt the methods (and conditions) as the activity 
of the whole replisome was lost in exploratory and control experiments.  
In conclusion, this thesis reports successful first steps of using fragments to 
functionally interrogate a complex molecular machine, contributing a new perspective 




7 Materials and methods 
7.1 Primase production 
Wild-type full-length E. coli primase-encoding pET3c based plasmid was received 
from the McGlynn group (University of York). �e gene was subcloned into the pET-
based pYSBL3C vector containing a hexahistidine tag followed by the 3C protease 
recognition site upstream from the insertion site. Linear dnaG and pYSBL3C were 
prepared by PCR amplification using primers 5ʹ-gttctgttccagggaccagcaATGGCTGGA 
CGAATCC and 5ʹ-catatgtgaggagaaggcgcgttaCTTTTTCGCCAGCTC for dnaG, and 
5ʹ-GGAAGTTCTGTTCCAGGGACCAGCAA and 5ʹ-CGCGCCTTCTCCTCACAT 
ATGGCTAGC for pYSBL3C. �e two linear fragments were then combined using 
the HiFi DNA Assembly Cloning kit (NEB) per the manufacturer protocol, using a 
plasmid to insert ratio of 1:2 and ~40 fmol of plasmid. BL21 competent cells were 
transformed with these plasmids and grown on LB agar containing kanamycin 
(35 µgmL-1) to select for successfully transformed cells. Presence of the insert was 
checked by colony PCR, and correctness of the inserts was confirmed by Sanger 
sequencing. Plasmid for primase RNA polymerase domain (RPD) (111-433), zinc-
binding domain (ZBD) (1-102), and helicase-binding domain (HBD) (433-581) were 
prepared in the same way by modifying the primers to anneal to the wanted regions of 
dnaG.  
For unlabelled protein, constructs were expressed in E. coli BL21(DE3) (Agilent) or 
BL21(DE3) pLysS (HBD), grown in Luria broth (1 L in 2.5 L baffled flasks) at 37 °C 
to an optical density of 0.6, by addition of 1-isopropylthiogalactopyranoside to 
0.2 mM. After 2-4 h at 37 °C or overnight at 18 °C, cells were harvested and stored at 
-80 °C until further use.  
For isotope-labelled protein, constructs were expressed in minimal media (M9 salts 
containing 15NH4Cl, supplemented with MgSO4, 12C- or 13C-glucose, essential trace 
elements, and Gibco vitamins mix) to obtain uniformly 15N-labelled or 15N-13C-
labelled protein.  
Purification of primase was performed in three steps. First, resuspended cells with 
added protease inhibitors (Roche) were lysed by sonication or by passage through a 
French press, the cleared lysate was applied to a HisTrap column (GE) pre-equilibrated 
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with buffer A (Tris pH 8 50 mM, NaCl 300 mM, 2-mercaptoethanol 5 mM, imidazole 
10 mM), and the bound primase eluted by a gradient up to 500 mM of imidazole in 
buffer A. Second, the affinity tag was removed by incubation with HRV 3C protease 
(50:1 molar ratio) at room temperature for 3 h and subsequent reapplication to a 
HisTrap column. �ird, the flow-through from the previous step was concentrated to 
1% of the column volume of a Superdex 75 (for ZBD and HBD) or 200 (for RPD and 
full-length) size exclusion column, then applied to it and eluted with buffer B (HEPES 
pH 7.5 20 mM, NaCl 50 mM, DTT 1 mM, EDTA 1 mM). Peak fractions of the final 
product were combined, concentrated, and stored at 4 °C or -20 °C. Full-length 
primase used for NMR screening and confirmation experiments still contained its N-
terminal tags. �e primase construct with attached tags had activity comparable to 
wild-type primase in the whole-replisome assay.  
7.2 DNA replication assay 
7.2.1 Template preparation 
�e template for this replication reaction was bacteriophage M13 in replicative form 
(RF) II, which facilitates a rolling circle mechanism of replication. It was prepared by 
annealing a partially overlapping oligonucleotide (5ʹ-(dT)36(f1-complement)30) to 
single-stranded M13mp18, then generating M13 RFII by complete extension of the 
primer by T4 polymerase lacking its exonuclease domain. �is produced a double-
stranded plasmid with a single nicked site at the primer. T4 polymerase was 
permanently inactivated by heating to 70 °C for 15 minutes.  
7.2.2 Replication reaction 
All replisome subunits were previously produced and purified by the McGlynn group 
and stored at >15x final assay concentrations in storage buffer (Tris pH 8 50 mM, NaCl 
100 mM, EDTA 1 mM, DTT 1 mM, glycerol 50%) at -80 °C. �e replication reaction 
mix was assembled on ice by mixing all replisome components, template, buffer, DTT, 
BSA, Mg2+, and all nucleotides except dATP and dTTP (Table 7-1). �e experiment 
was started by addition of the reaction mix to the fragment (0.5 mM) or to DMSO (the 
final concentration of DMSO was 2.5% in all reactions). �e reaction mix was 
incubated at 37 °C for 3 minutes for equilibration. �en, the reaction was started by 
the addition of dATP and dTTP to 40 µM. �e reaction was allowed to proceed for 3 
minutes in order to prevent the initial burst of unstable replisome complexes from 
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contributing to the signal. �en, α-32P-dCTP (33 nM) was added to the reaction mix 
for subsequent detection of reaction products. After another 10 minutes, the reaction 
was terminated by addition of either EDTA to 45 mM or NH4OAc to 2.3 M, depending 
on the method of detection (Figure 7.1).  
Table 7-1. Components of the whole-replisome DNA replication assay. 
Component Final concentration (monomers) 
Pol III core (αεθ) 50  nM 
Clamp loader (τ3δδʹψχ) 25  nM 
Helicase DnaB 160  nM 
Helicase loader DnaC810 160  nM 
SSB 1  µM 
Primase DnaG 200  nM 
Sliding clamp (β) 80  nM 
BSA 0.1  mgmL-1 
M13 RFII 2  nM 
HEPES pH 8 (4 °C) 40  mM 
DTT 10  mM 
Mg(OAc)2 10  mM 
ATP 2  mM 
GCUTP 0.2  mM 
dCdGTP 40  µM 
dAdTTP 40  µM 
α-32P-dCTP 0.03  µM 
 
7.2.3 Measurement of replication products 
To measure 32P incorporation into all reaction products, reaction mix terminated with 
EDTA was precipitated by addition of ice-cold trichloroacetic acid (TCA) (5%). TCA 
will precipitate all icosamer and larger oligonucleotides. Precipitated reaction product 
suspensions were filtered through glass microfibre filters, which were then washed 
with ice-cold TCA (1%) and ethanol, and finally air-dried. Reaction products were 
quantified by measuring Cherenkov radiation using a liquid scintillation spectrometer 




Figure 7.1. Schematic representation of the workflow used during screening of the fragment 
library in the whole-replisome assay and subsequent confirmation experiments. The DNA 
elongation reaction is explained in section 1.2 and Figure 2.1. From the start, all reaction 
tubes contained all components listed in Table 7-1 except those mentioned explicitly in this 
figure. For screening and confirmation, total products were quantified as in 1). For 
quantification and visualisation of separate leading and lagging strands, method 2) was used.  
To separate leading strand products from lagging strand products, reaction mix 
terminated with NH4OAc was precipitated by adding ice-cold ethanol to 70%, 
followed by a wash (70% ethanol) of the pellet to remove most of the remaining free 
α-32P-dCTP. �e precipitated reaction products were run on alkaline (50 mM NaOH) 
agarose gel (0.7%) overnight, which was then dried and imaged onto a 
photostimulable phosphor plate for detection (Personal Molecular Imager, Bio-Rad). 
Data were quantified using ImageQuant TL software version 8 (GE) by counting total 
pixel intensities for each row of pixels down each manually demarcated lane or band, 
yielding 2D graphs representing amount of product per Rf.  
7.2.4 Calculation of inhibition constants 
Total amounts of detected reaction products at each concentration of fragment were 
transformed into fraction of the control reaction (DMSO), which were then averaged 
over 2-4 independent repeats. IC50 values were calculated by fitting the averaged data 
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points to the following sigmoidal dose-response model using Graphpad Prism 
version 8: 
𝐼𝐼𝐼𝐼ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝐼𝐼 = 𝑌𝑌0 +
(𝑌𝑌𝑚𝑚𝑚𝑚𝑚𝑚 − 𝑌𝑌0)
1 + 10(log 𝐼𝐼𝐼𝐼50−log[𝑓𝑓𝑓𝑓𝑚𝑚𝑓𝑓𝑚𝑚𝑓𝑓𝑓𝑓𝑓𝑓])−𝑝𝑝
 
where Y0 and Ymax are the bottom and top of the curve, respectively, IC50 is the X 
value halfway between Y0 and Ymax, and p is the Hill slope. �e Hill slope was fixed 
to 1.  
7.3 Primase activity assay 
Primase alone has insufficient primer synthesis activity to yield reliable product signal 
even after washing and gel electrophoresis, therefore DnaB helicase was included in 
this assay. �e primer template was ssDNA of sequence (CT)17GCAAAGC, resulting 
in a full-length complementary RNA primer product of 35 b. �is template or 
template-primer duplex is not expected to be a substrate to helicase, therefore the only 
role of helicase in this assay is to bind primase.  
Assay conditions were kept as close as possible to those of the whole replisome 
reaction. �e primer synthesis reaction mix was assembled on ice by mixing template 
(0.2 µM), buffer, DTT, BSA, Mg2+, all (deoxy-)nucleotides (ATP final concentration 
was lowered from 2 mM to 0.2 mM), and α-32P-GTP (33 nM/35 µCi). �e experiment 
was started by addition of the reaction mix to the fragment or to DMSO (the final 
concentration of DMSO was 2.5% in all reactions). �e reaction mix was incubated at 
37 °C for 3 minutes for equilibration. �en, the reaction was started by the addition of 
primase to 200 nM and helicase to 160 nM. �e reaction was allowed to proceed for 
1 h, after which the reaction was terminated by addition of NH4OAc to 2.3 M. reaction 
product was precipitated by ethanol precipitation in a test tube, followed by a wash of 
the pellet to remove most of the remaining free α-32P-GTP. �e reaction products were 
run on denaturing (7 M urea) 18-20% polyacrylamide gel, which was then dried and 
imaged onto a photostimulable phosphor plate for detection (Personal Molecular 





Samples (550 µL) were prepared in protein storage buffer unless otherwise specified 
and contained 3-trimethyl-silyl-propane 1-sulfonic acid (DSS) (0.1 mM) and D2O 
(5-10%). Compounds were added from neat stocks or 200 mM stocks in deuterated 
DMSO. �e sample temperature was 298 K. NMR data were collected on a 700 MHz 
Bruker Avance Neo spectrometer, equipped with a 5 mm triple-resonance N2-cooled 
cryoprobe.  
7.4.1 Compound quality controls 
Fragments were diluted to 500 µM into QC buffer (NaPi pH 7 80 mM, D2O 10%, DSS 
100 µM). Proton spectra were recorded with water suppression by excitation sculpting 
(Hwang & Shaka, 1995) with 16-32 scans, a spectral width of 16 ppm, an acquisition 
duration of 2 s, and a recycle delay of 8 s. All analysis was done using Bruker TopSpin 
software version 3.5.6 or 4.0.2. Fragments were evaluated as ‘passed’ if their spectra 
were identical to their original spectra recorded when their stock solutions were first 
prepared.  
7.4.2 Ligand-observed experiments 
All samples contained purified protein (15-20 µM) exchanged into fresh buffer: either 
NaPi or Tris or HEPES at pH 7.5, NaCl (50 mM), MgCl2 (10 mM), DTT (1 mM), DSS 
(0.1 mM), D2O (5%), compound (0.5-1 mM), and DMSO-d6 (0.25-1.5%). For 
WaterLOGSY experiments, the ephogsygpno pulse program (Dalvit et al., 2000) was 
used with a mixing time of 1.5 s. For saturation transfer difference (STD) experiments, 
the protein saturation frequency peak was set to 0.5 ppm downfield of the transmitter 
frequency and a gaussian pulse shape was used. For Carr-Purcell-Meiboom-Gills 
(CPMG) experiments, the filter delay was set to 1 s. Fragment screening against full-
length primase was conducted at the Crick Institute (London, UK) using a 700 MHz 
Bruker Avance III HD equipped with a cryo-probe and a SampleJet 96 well plate array 
autosampler. �e screening buffer consisted of NaPi (25 mM) pH 7.5, NaCl (45 mM), 




7.4.3 Protein-observed experiments 
Data for the ZBD were collected on a 500 MHz Bruker Avance I equipped with a 
room temperature BBI probe. For the ZBD, the hsqcetgpsi pulse program with water 
suppression was used (Schleucher et al., 1994; Kay et al., 1992), with 96 scans, 2048 
and 512 complex points per experiment, and an F1 offset and spectral width of 120 
and 32 ppm respectively. For the HBD, 1H-15N correlation spectra were recorded using 
the SOFAST experiment (Schanda et al., 2005) with 8 scans, 2048 and 256 complex 
points per experiment, and an F1 offset and spectral width of 120 and 40 ppm 
respectively. 1H-15N-13C HNCO spectra were recorded using the hncogpwg3d pulse 
program (Kay et al., 1994; Grzesiek & Bax, 1992), with 8 scans, 5% or 15% non-
uniform sampling, 2048, 128, and 256 complex points per experiment, F1 offset and 
spectral width of 174 and 12 ppm respectively, and F2 offset and spectral width of 118 
and 28 ppm respectively. Data were processed using Topspin and analysed using 
CcpNmr Analysis v2 (Vranken et al., 2005). �e position of the main DSS peak was 
used as an internal zero-frequency reference and published Ξ values were used for 
extension to indirect dimensions (Markley et al., 1998).  
7.5 MD simulations 
Fragment parametrisation was done using Gaussian09 with the HF/6-31G* basis set 
(Hariharan & Pople, 1973; Francl et al., 1982) for calculation of electrostatic 
potentials. Further work was done using several programs within the Amber14 or 
AmberTools17 program suites (Case et al., 2014). Antechamber was used for 
normalisation of Gaussian output into restrained electrostatic potentials (Bayly et al., 
1993), and missing bonding/angles parameters were added manually. Homology 
modelling of the E. coli ZBD (residues 2-101) was done in MOE version 2016.0802 
based on the crystal structure of the G. stearothermophilus homologue (Pan & Wigley, 
2000). Parameters for the zinc ion were added manually based on reported values for 
zinc in CHC2-type zinc binding proteins. Systems were prepared by placing one 
protein and one ligand molecule in different orientations at least 5 Å away from each 
other. Leap was used to solvate these models in explicit TIP3P water in an octahedron 
with at least 4 Å distance between any non-solvent atom and the box boundaries. Na+ 
and Cl- ions were added to effective concentrations of 33-44 mM to neutralise the 
system. Proteins were described using the AMBER ff14SB forcefield (Maier et al., 
2015). Systems were energy-minimised then heated from 100-300 K in four steps of 
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200 ps at constant volume, then vacuums were removed in one step of 1 ns at constant 
pressure of 1 atmosphere. Temperature was kept at 300 K employing Langevin 
dynamics with a collision frequency of 4 ps-1 (Izaguirre et al., 2001). Simulations were 
run for 500 ns for each system (8 in total, 4 per protein) at constant volume, using 
SHAKE (Ryckaert et al., 1977) to allow for time steps of 2 fs, writing information 
only once per 40 ps to reduce calculation times. All simulations were run using the 
particle mesh Ewald (PME) method (Darden et al., 1993) (direct space sum cut-off 
9 Å) on NVIDIA Tesla K80 graphics processing units (Salomon-Ferrer et al., 2013) 
on the Minotauro cluster of the Barcelona Supercomputing Center. Calculation times 
varied between 20-100 ns per day depending on the number of atoms in the system 
and the number of available nodes. Trajectory analyses were done using cpptraj (Roe 
& Cheatham, 2013).  
7.6 SEC-MALS 
All SEC-MALS experiments were conducted by the University of York Department 
of Biology Biotechnology Facility. Experiments were conducted on a system 
comprising a Wyatt HELEOS-II multi-angle light scattering detector and a Wyatt rEX 
refractive index detector linked to a Shimadzu HPLC system. Work was conducted at 
room temperature (20 ±2 °C). �e column (Superdex 75 or 200 analytical grade) was 
equilibrated with at least 2 column volumes of protein storage buffer before use and 
flow was continued at the working flow rate until baselines for UV, light scattering 
and refractive index detectors were all stable. Sample injection volume was 100 µL. 
Shimadzu LC Solutions software was used to control the HPLC and Astra V software 
for the HELEOS-II and rEX detectors. Data were analysed using the Astra V software. 
Molecular weights were estimated using the Zimm fit method with degree 1. A control 
sample of bovine serum albumin (BSA) was run to correct for changes in instrument 
calibration and dn/dc values in the buffer used.  �e molecular weight of BSA was 
taken as 66,400 Da.  
7.7 Mass spectrometry 
All MS experiments were conducted by the University of York Department of Biology 
Biotechnology Facility Metabolomics & Proteomics centre. Samples were diluted 1 in 
10 with aqueous 50% (v:v) acetonitrile containing 1% (v:v) formic acid before 
infusing at 3 µLmin-1 into a Bruker maXis-HD qTOF mass spectrometer using 
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electrospray ionisation. Positive ESI-MS spectra were averaged over a 1 min 
acquisition before maximum entropy deconvolution. Deconvoluted mass spectra were 
peak picked to monoisotopic masses using the SNAP algorithm (repetitive building 
blocks C4.9384; N1.3577; O1.4773; S0.0415; H7.7583), requiring a minimum signal 
to noise ratio and minimum percent relative intensity of 10. Instrument control, data 
acquisition and processing were performed using Compass 1.7 software (microTOF 
control and DataAnalysis, Bruker Daltonics).  
7.8 Crystallography 
All crystallisations were set up using the sitting drop vapour diffusion method. 200 nL 
drops with equal volumes protein:precipitant were prepared using a Mosquito liquid 
handler (SPT Labtech). Purified RPD (aa 111-433 or 111-429) (7-15 mgmL-1) was 
subjected to several broad crystallisation screens that were commercially available. A 
crystal cluster that grew from an impurity in bicine pH 9 (0.1 M) + PEG6000 (20%) 
(JCSG+ screen, Molecular Dimensions) was used for seeding in the same condition, 
which yielded a single crystal in the I222 space group (a/b/c = 69.8/73.3/129.2 Å). 
Optimisation of the condition included varying the pH between 8.5-9.0, PEG 
concentration up to 24%, addition of ethylene glycol up to 20%, and varying the 
protein:reservoir volume ratios. In all these trials, however, crystals only grew in the 
P212121 space group again (a/b/c = 38/57/135-148 Å) where the c axis length varied 
depending on soaking conditions. Soaking was performed by adding mother liquor 
mixed with up to 50% compound stock (200 mM in DMSO for fragments, or 100 mM 
in water for nucleotides) to the crystal drops. Bigger crystals often cracked upon 
addition of compound. Slow increase of compound concentrations was found to be the 
best way to preserve crystals. After soaking overnight, crystals were frozen directly 
into liquid nitrogen.  
All datasets were collected at the Diamond Light Source. Some crystals were centred 
manually to avoid irradiating cracks which would give multiple diffraction patterns. 
Data were collected in 0.1° slices up to 220° with no beam attenuation. Data 
processing was done in CCP4i2 and consisted of automatic integration, scaling and 
merging using the XDS 3dii pipeline, data reduction in Pointless/Aimless, molecular 
replacement in Molrep using a previously solved apo model with a matching c axis, 
and refinement in Refmac and Coot. Where possible, the same FreeR set derived from 
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an apo dataset was used for all compound-soaked datasets to avoid biases. Datasets 
that were almost completely isomorphous to available apo models were processed 
using the automated ligand solution workflow within CCP4i2. Resolution cut-offs for 
refinement were based on anisotropic CC1/2 statistics. A small number of crystals 
showed signs of radiation damage as evidenced from increased Rmerge values of later 
images. �ese images were then excluded while still preserving at least 90° of data. 
To judge the presence of difference density that could accommodate the soaked 
molecule, datasets were subjected to one round of refinement and manual model 
building. Statistics for a representative dataset (soaked in 10% DMSO overnight) after 
one round of automatic and manual refinement are given in Table 7-2. 
Table 7-2. Data collection and refinement statistics for primase RPD (111-433) soaked in 10% 
DMSO.  
Data collection  
Space group P212121 
a, b, c (Å) 38.00, 57.95, 145.42 
Resolution (Å) 1.95 (2.00-1.95) 
Rmerge (%) 9.2 (24.4) 
I / σ(I) 9.7 (0.9) 
CC1/2 (%) 99.8 (36.0) 
Completeness (%) 100 (100) 
Redundancy 8.0 (8.3) 
Refinement  
Resolution (Å) 1.95 
Number of unique reflections 24356 (1718) 
Rwork / Rfree (%) 22.5 / 27.6 
Number of protein atoms 2538 
Number of waters 43 
B-factors (Å2)  
Protein 48.95 
Water 47.71 
RMS bond length deviation (Å) 0.01 
RMS bond angle deviation (°) 1.41 
Ramachandran (favoured/allowed/disallowed) 311/5/2 
 
7.9 Synthesis of diazirine analogues and UV crosslinking experiments 
�e author of this manuscript gratefully acknowledges the contributions of Dr. James 
D. Firth to results presented in section 5.2, i.e. the design and synthesis of compounds 
D1, D2, D3, D4, and other derivatives of various replisome fragment inhibitors. All 
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compounds and intermediate reagents were characterised by infrared spectroscopy, 1H 
and 13C NMR spectroscopy, and high-resolution ESI-MS.  
Compounds (0.5 mM in NMR QC buffer unless otherwise specified) and reaction 
mixtures were irradiated with UV-B light (peak 302 nm, range 280-350 nm) in a 
CL-1000 ultraviolet crosslinker (1 mJcm-2) (UVP) at room temperature. For 
incubation times longer than 10 minutes, irradiation resulted in an increase in chamber 
temperature from 22 °C to a maximum of 28 °C. Samples were kept in open 
transparent containers during irradiation. After irradiation, samples were either 
immediately used in subsequent experiments (replication assays, NMR) or stored at 
4 °C until further use (MS).  
7.10 Click reactions 
Alkyne-tagged diazirine-protein mixtures were used directly after UV crosslinking. 
To each mixture were added to final concentrations: CuSO4 (aqueous stock) 1.5 mM, 
tris((1-benzyl-4-triazolyl)methyl)amine (TBTA) (DMSO stock) 1.5 mM, TAMRA-
azide dye (DMSO stock) 30 µM, ascorbic acid (fresh aqueous stock) 1.5 mM. Click 
reaction mixtures were incubated at 40 °C for 1 h, then diluted with Laemmli sample 
buffer and directly used for gel electrophoresis.  
7.11 Covalent fragment screening 
Electrophilic fragments were provided by the Keserű group (Research Centre for 
Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary) as 100 mM 
DMSO stock solutions. For storage periods longer than one month, these fragments 
were stored in argon atmosphere at -20 °C. All replication reaction methods and 
materials were identical to those used in previous experiments (see section 7.2) (BSA 






























































































































































































































































aa – amino acid 
ApCpp – adenosine 5ʹ-(α,β-methyleno)triphosphate 
bp – base pair 
BSA – bovine serum albumin 
CSP – chemical shift perturbation 
CTD – carboxy-terminal domain 
DMSO – dimethylsulfoxide 
dsDNA – double-stranded DNA 
DSS – 3-trimethyl-silyl-propane 1-sulfonic acid 
DTT – dithiothreitol 
FBLD – Fragment-based lead discovery 
FL – full-length 
GpCpp – guanosine 5ʹ-(α,β-methyleno)triphosphate 
GppNHp – guanosine 5ʹ-(β,γ-imido)triphosphate 
HA – heavy atom 
HBD – helicase-binding domain 
HSQC – heteronuclear single quantum coherence 
HTS – high-throughput screening 
IC50 – 50% inhibitory concentration 
ITC – isothermal titration calorimetry 
KD – equilibrium dissociation constant 
LE – ligand efficiency 
LO – ligand-observed 
MD – molecular dynamics 
MS – mass spectrometry 
NMR – nuclear magnetic resonance 
NTD – amino-terminal domain 
PO – protein-observed 
pol III HE – polymerase III holoenzyme 
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ppGpp – guanosine 3ʹ,5ʹ-bispyrophosphate 
PPI – protein-protein interaction 
rmsd – root mean square deviation 
RPD – RNA polymerase domain 
SAR – structure-activity relationships 
SEC-MALS – size exclusion chromatography-multi-angle light scattering 
SPR – surface plasmon resonance 
SSB – Single-stranded DNA-binding protein  
ssDNA – single-stranded DNA 
TSA – thermal shift assay 
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